Top

William Plunkett, Ph.D.

Department of Experimental Therapeutics, Division of Cancer Medicine

About Dr. Plunkett

William Plunkett, Ph.D., Professor at The University of Texas MD Anderson Cancer Center, holds the Barnts Family Distinguished Chair for Cancer Research . His administrative appointment is Deputy Chairman, Department of Experimental Therapeutics.

My major research pursuits are related to development of novel therapeutics based on knowledge of cellular responses to DNA damage, andelucidating the mechanisms of drug action, particularly of nucleoside analogs. Investigations by my group demonstrated multiple mechanism of action for both fludarabine and gemcitabine, as well as the mechanisms of other nucleosides. I have enjoyed sustained and dedicated collaborations with his colleagues involved with clinical research, interactions that have resulted in advances in clinical treatments that induce remissions more effectively and are maintained them longer than previously possible in leukemias.I was the recipient of the Service to Mankind Award from the Leukemia Society of America in 1989, the Faculty Achievement Award in Clinical Research in 1996, and the1^stPotu N. Rao award for Excellence in Basic Research in 2006, and the Waun Ki Hong Achievement Award for Team Research - CLL in 2011. I was elected a Fellow of the American Association for the Advancement of Science in 2012. I was the 2013 recipient of the Charles A. LeMaistre, M.D. Outstanding Acheivement Award in Cancer and received the John Mendelsohn Lifetime Scientific Achievement Award in 2016. Under the title of Associate Vice President, Research Integrity, I have assumed the responsibilities of the Institutional Research Integrity Officer since 2007.

I am particularly interested in education of the next generation of scientists. He has been a member of the University of Texas Graduate School of Biomedical Sciences at Houston since 1976. His activities in graduate education have been recognized by his election to President of the Faculty of The Graduate School of Biomedical Sciences, and the award of the 1^stSowell-Huggins Professorship in Cancer Research in that school. I was the recipient of the Distinguished Research Faculty Mentor Award in 2013.

Primary Appointment

Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor (Joint appointment), Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Barnts Family Distinguished Chair for Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Member of Graduate Faculty, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX

Research Interests

My research program melds discovery of mechanisms of drug action and an understanding of cancer cell biology to generate experimental strategies that improve therapeutic efficacy and aim to overcome potential means of tumor resistance. I have concentrated efforts on translational investigations with colleagues in the Leukemia Department.

Inhibition of DNA Repair.We have discovered that the mechanism of action of a nucleoside analogue now in early phase clinical trials, sapacitabine, is to generate a single strand break which is difficult to repair, and results in formation of a double-strand DNA break upon subsequent DNA replication. A homologous recombination mechanism is required to repair such lesions. Based on this information, we have initiated investigations of sapacitabine in tumors that lack the homologous recombination repair functions.

Cellular context as a basis for specificity.The survival of CLL is dependent upon the sustained expression of anti-apoptotic proteins, some of which (Mcl-1, XIAP) have intrinsic signals for rapid turnover of transcripts and protein. We reasoned that transient inhibition of transcription would decrease these proteins to the point of initiation of apoptosis, an irreversible process. Transcription requires phosphorylation of RNA polymerase II by cyclin-dependent kinase 9. Our investigations in primary CLL samples demonstrated that Cdk9 is potently inhibited by several small molecules, with a resulting decrease in RNA polymerase activity, transcript generation and decreased survival protein levels, that were associated with apoptosis induction within 8 hr. This has provided rationale for the development of this class of novel therapeutics in hematological malignancies.

Education & Training

Degree-Granting Education

1970	University of Massachusetts, Amherst, Massachusetts, US, Biochemistry, Ph.D
1965	Springfield College, Springfield, Massachusetts, US, Biology, Chemistry, BS

Postgraduate Training

1970-1971	Postdoctoral Fellow, Therapeutic Research, University of Pennsylvania, Philadelphia, Pennsylvania
1967-1967	Research Fellowship, Physiology Course, Woods Hole Marine Biological Laboratory, Wood Hole, Massachusetts

Experience & Service

Academic Appointments

Professor, Department of Clinical Investigation, The University of Texas MD Anderson Cancer Center, Houston, TX, 1993

Pharmacologist, Department of Clinical Investigation, The University of Texas MD Anderson Cancer Center, Houston, TX, 1993

Hubert L. and Olive Stringer Professorship in Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1989 - 1999

Professor, Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1989

Pharmacologist, Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1989

Professor, Department of Experimental Therapeutics, The University of Texas System Cancer Center, Houston, TX, 1986

Pharmacologist, Department of Medical Oncology, The University of Texas System Cancer Center, Houston, TX, 1986

Associate Biochemist, Department of Chemotherapy Research, The University of Texas System Cancer Center, Houston, TX, 1983

Associate Professor, Department of Chemotherapy Research, The University of Texas System Cancer Center, Houston, TX, 1983

Associate Biochemist, Department of Developmental Therapeutics, The University of Texas System Cancer Center, Houston, TX, 1980

Associate Professor, Department of Developmental Therapeutics, The University of Texas System Cancer Center, Houston, TX, 1980

Assistant Professor, Department of Developmental Therapeutics, The University of Texas System Cancer Center, Houston, TX, 1975

Administrative Appointments/Responsibilities

Director, Therapeutics and Pharmacology Program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, 2017 - Present

Developmental Therapeutics Program, CCSG Award P30 CA16672, Leader, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present

CLL Moon Shot, Co-leader, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2020

Deputy Department Chair, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - Present

Associate Vice President, Research Integrity, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - Present

Graduate, Faculty Leadership Academy, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2008

Institutional Research Integrity Officer, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - Present

Director of Research Development, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2008

Chief, Section of Cellular & Molecular Pharmacology, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 1993 - 2004

Other Appointments/Responsibilities

Member, Advisory Board, Xanthus Pharmaceuticals, Cambridge, MA, 2007

Member, AstraZeneca Gateway 3 Oncology Emerging Product Team Clinical and Translational Strategy Group, Waltham, MA, 2005 - 2006

Chairman, Scientific Advisory Board, Chronic Lymphocytic Leukemia Global Research Foundation, Houston, 2004 - Present

Research Associate, University of Colorado Medical Center, Denver, CO, 1972 - 1975

Institutional Committee Activities

Co-Chair, Search Committee for Vice President, Therapeutics Discovery, 2015 - 2016

member, Science that enables - research space metrics, 2014 - Present

member, Advisory Committee for Search for Head of Division of Cancer Medicine, 2014 - Present

Chairman, Selection Committee, Charles A. LeMaistre, M.D. Outstanding Achievement Award in Cancer, 2014

member, Ethics Monitoring Group, 2012 - Present

member, Historical Resources Steering Committee, 2012 - 2019

Member, Faculty Awards Committee, 2011 - Present

Chair, Search Committee for Sr. Vice President for Academic Affairs, 2011

Vice Chair, Research Laboratory Space Committee of the Research Council, 2010 - 2013

Member, Endowed Positions Advisory Committee, 2010 - 2013

Member, Graduate Education Committee, 2010 - 2013

Member, Cell Line Authentication Committee, 2009 - 2011

Member, Executive Committee, Graduate School of Biomedical Sciences, 2009 - 2011

Co-Chair, Executive Research Compliance Committee, 2009 - Present

Chair, Patent Ethics Review Committee, 2009 - Present

Member, Multidisciplinary Research Project Review Committee, 2007 - 2010

Member, Faculty Senate-Faculty Achievement Awards Selection Committee, 2007 - 2012

Member, TRIUMPH Postdoctoral Training, 2007 - 2016

Member, Research Laboratory Space Committee of the Research Council, 2007 - 2010

Member, Multi-disciplinary Research Grant Committee, 2007 - 2010

Member, Promotion and Tenure Committee, 2006 - 2007

Member, Radioactive Drug Research Committee, 2006 - 2007

Member, President's Committee to Review Patent & Intellectual Property Policies, 2005 - 2007

Vice Chair, Patent Ethics Committee, 2005 - 2009

Member, Office of Research Administration Advisory Committee, 2005 - 2007

Member, Cultural Principles Working Group, 2004

Member, Clinician-Investigator Program Advisory Committee, 2004 - 2010

Member, Translational Research Faculty Development Committee, 2003 - 2005

Past Chair, Conflict of Interest Committee, 2003 - 2004

Chairman, Conflict of Interest Committee, 2002 - 2003

Member, Conflict of Interest Challenges Committee, 2002 - 2003

Member, Promotion and Tenure Committee, 2001 - 2004

Member, Endowed Positions Committee, 2001 - 2004

Vice-Chairman, Conflict of Interest Committee, 2001 - 2002

Member, ex officio, Conflict Management Advisory Committee, 2001 - 2002

Member, Ombudsman Selection Committee, 2000

Alternate, Executive Committee of the Science Faculty, Dept. of Experimental Therapeutics, 2000 - 2004

Member, Clinical and Translational Research Center Review Committee, 2000 - 2003

Member, Intellectual Property Oversight Committee, 2000

Chairman, Conflict Management Advisory Committee, 2000 - 2001

Chairman, Subcommittee of the FPGR Committee, 1999

Chairman, Implementation Subcommittee of the FPGR Committee, 1999

Member, Faculty Senate Subcommittee on Faculty Achievement Awards: Clinical Research, 1999

Member, Monsanto Research Grant Review Board, 1999 - 2000

Chairman, Faculty Peer and Grievance Review Committee (FPGR), 1998 - 2000

Member, Executive Committee of the Science Faculty, Defining the NTRA Description, 1998

Member, President's Recruitment Advisory Committee, 1998

Member, Committee to Define the Tumor Institute, 1998

Member, Search Committee for the Dean of the Graduate School of Biomedical Sciences, 1998

Member, Search Committee for the Chairman of the Department of Carcinogenesis, 1998

Member, Committee on Configuration of Basic Science Departments at MDACC, 1998

Member, Selection Committee, Texas Federation of Business and Professional Women's Club Award, 1998 - 2007

Member, MD Anderson Faculty Associates Trainee Recognition Day Selection Committee, 1998 - 2002

Member, Committee on Export of Patient Material for Commercial Use, 1998

Member, Institutional Compliance Committee, 1998

Member, Chief Academic Officer Advisory Committee, 1997

Chairman, Department of Clinical Investigation Research Seminar Series, 1997 - 1998

Member, Criteria for Academic Excellence Working Group, 1997

Member, Faculty Compensation Project, 1997 - 2001

Member, Search Committee for Head of Division of Surgery, 1997

Member, MD Anderson Faculty Associates Trainee Recognition Day Abstract Review, 1997

Chairman, Faculty Senate Subcommittee on Faculty Achievement Awards: Clinical Research, 1997

Chairman, Subcommittee on Criteria and Mechanisms for Allocation of Research Resources: Institutional Research Retreat, 1997

Member, Grant Management Subcommittee of the Executive Committee of the Science Faculty, 1996 - 1996

Chairman, Conflict of Interest Committee, 1996 - 1998

Member, Institutional Directions Working Group, 1995 - 1996

Member, Clinical Research Committee, 1995 - 1996

Member, Conflict of Interest Committee, 1995 - 1998

Member, Search Committee for Vice President for Academic Affairs, 1994 - 1996

Member, Endowed Positions Advisory Committee, 1994 - 1997

Vice Chairman, Executive Committee of the Science Faculty, 1994 - 2000

Chairman, Space Reallocation Subcommittee of the Executive Committee of the Science Faculty, 1994

Member, Revenue Enhancement Subcommittee of the Executive Committee of the Science Faculty, 1994 - 1996

Member, Faculty Committee for Graduate Education, 1993 - 1996

Member, Physicians Referral Service Scientific Review Committee, 1993 - 1995

Member, Intramural Committee for Assessment of Grants and Contracts, 1993 - 1994

Member, Oversight Committee for the Cancer Therapeutics and Discovery Program and the Pharmaceutical Development Center, 1993 - 2002

Representative, Human Resources Advisory Group, Subcommittee of the Executive Committee of the Science Faculty, 1992 - 1994

Member, Education Evaluation Subcommittee of the Executive Committee of the Science Faculty, 1990

Chairman, Division of Medicine Promotions Committee, 1990

Member, Implementation Team of Strategic Planning Initiative, 1989

Member, Joint Appointments Subcommittee of the Executive Committee of the Science Faculty, 1989

Member, Classifications and Titles Subcommittee of the Executive Committee of the Science Faculty, 1988

Representative, Institutional Risk Management Committee, Subcommittee of the Executive Committee of the Science Faculty, 1988 - 1989

Member, Institutional Strategic Agenda - Administrative Infrastructure Committee, 1988 - 1989

Member of Faculty Accrediting Committee, Southern Association of Colleges and Schools, 1988 - 1989

Member, Division of Medicine Promotions Committee, 1987 - 1998

Member, Materials Management Oversite Subcommittee of the Executive Committee of the Science Faculty, 1987

Member, Research Space Allocation Subcommittee of the Executive Committee of the Science Faculty, 1986

Chairman, Position Classification of Research Laboratory Personnel Subcommittee of the Executive Committee of the Science Faculty, 1986

Member, Intellectual Property Committee, 1986 - 1989

Member, Clinical Immunology and Biological Therapy Chairman Search Committee, 1986 - 1987

Member, Biomedical Research Support Grant Committee, 1985 - 1999

Chairman, Department of Chemotherapy Research Seminar Series, 1985 - 1986

Member (Division of Medicine representative), Executive Committee of the Science Faculty, 1984 - 2000

Chairman, Faculty Classification (Promotions & Tenure) Committee, 1983 - 1984

Chairman, MD Anderson Research Committee, 1983 - 1984

Member, Faculty Classification (Promotions & Tenure) Committee, 1982 - 1985

Co-Chairman, Biochemistry Chairman Search Committee, 1982 - 1983

Member, Institutional Research Grant Committee, 1981 - 1984

Member, Committee on Institutional Objectives-Basic Sciences, 1981 - 1982

Chairman, Research Seminar Committee, 1981 - 1982

Member, Virology Chairman Search Committee, 1980 - 1983

Member, Research Seminar Committee, 1980 - 1983

Member, Fundamental Research Symposium Committee, 1980 - 1981

Member, MD Anderson Research Committee, 1980 - 1985

Honors & Awards

2018	Dr. John S. McMurray Lifetime TAP Achievement Award, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences
2016	John Mendelsohn Lifetime Scientific Achievement Award, Division of Cancer Medicine
2013	Charles A. LeMaistre M.D. Outstanding Achievement Award in Cancer, M.D. Anderson Cancer Center
2013	Distinguished Research Faculty Mentor Award, M.D. Anderson Cancer Center
2012 - 2020	Co-Leader of CLL Moon Shot Program, M.D.Anderson Cancer Center Moon Shot Program
2012	Fellow, American Association for the Advancement of Science, American Association for the Advancement of Science
2011	Waun Ki Hong Achievement Award for Team Science - CLL, Division of Cancer Medicine
2006	1st Potu N. Rao Award for Outstanding Achievement in Basic Science, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine
2001	1st Sowell-Huggins Professorship in Cancer Research, University of Texas Graduate School of Biomedical Sciences, Houston
1999 - 2024	Barnts Family Distinguished Chair for Cancer Research, The University of Texas M. D. Anderson Cancer Center
1996	Faculty Achievement Award, Clinical Research, The University of Texas M. D. Anderson Cancer Center
1993	Chairman, Gordon Research Conference on Purines, Pyrimidines & Related Substances
1991	Outstanding Faculty Award, University of Texas Graduate School of Biomedical Sciences at Houston
1989 - 1999	Hubert L. and Olive Stringer Professorship in Medical Oncology, The University of Texas M. D. Anderson Cancer Center
1989	Service to Mankind Award, Leukemia Society of America, Gulf Coast Chapter
1988 - 1989	President of the Graduate Faculty, University of Texas Graduate School of Biomedical Sciences

Professional Memberships

Society of Hematological Oncology

2012 - Present

Graduate School of Biomedical Sciences

2012 - 2012

Major Review of Molecular Carcinogenesis

2012

International Working Group on CLL

2009 - Present

International Society for Nucleosides, Nucleotides and Nucleic Acids

2000 - 2016

American Society of Hematology

1991 - 2008

International Society for Antiviral Research

1989 - 1995

Southern Association of Colleges and Schools Faculty Accrediting Committee

1988 - 1989

American Society for Clinical Oncology

1982 - 1991

Biochemical Modulation Advisory Group, National Cancer Institute, National Institutes of Health

1982 - 1988

American Society for Pharmacology and Experimental Therapeutics

1978

The University of Texas MD Anderson UTHealth Graduate School of Biomedical Science

1977 - Present

American Association for Cancer Research

1976 - 2005

American Association for the Advancement of Science

1966

Selected Publications

Peer-Reviewed Articles

Thompson PA, Bazinet A, Wierda WG, Tam CS, O'Brien SM, Saha S, Peterson C, Plunkett W, Keating MJ. Sustained remissions in CLL after frontline FCR treatment with very long-term follow-up. Blood. e-Pub 2023. PMID: 37595283.
Chen R, Chen Y, Xiong P, Zheleva D, Blake D, Keating MJ, Wierda WG, Plunkett W. Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells. Leukemia 36(6):1596-1608, 2022. e-Pub 2022. PMID: 35383271.
Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
Chen R, Tsai J, Thompson PA, Chen Y, Xiong P, Liu C, Burrows F, Sivina M, Burger JA, Keating MJ, Wierda WG, Plunkett W. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. Blood Cancer J 11(3):57, 2021. e-Pub 2021. PMID: 33714981.
Liu X, Jiang Y, Nowak B, Ichikawa S, Ohtawa M, Matsuda A, Plunkett W. Repair of DNA damage induced by the novel nucleoside analogue CNDAG through homologous recombination. Cancer Chemother Pharmacol. e-Pub 2020. PMID: 32072218.
Banerjee P, Zhang R, Ivan C, Galletti G, Clise-Dwyer K, Barbaglio F, Scarfò L, Aracil M, Klein C, Wierda W, Plunkett W, Caligaris-Cappio F, Gandhi V, Keating MJ, Bertilaccio MTS. Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. Cancer Immunol Res 7(12):2036-2051, 2019. e-Pub 2019. PMID: 31530560.
Liu X, Jiang Y, Takata KI, Nowak B, Liu C, Wood RD, Hittelman WN, Plunkett W. CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death. Mol Cancer Ther 18(12):2283-2295, 2019. e-Pub 2019. PMID: 31501277.
Luo Y, Yang Y, Liu M, Wang D, Wang F, Bi Y, Ji J, Li S, Liu Y, Chen R, Huang H, Wang X, Swidnicka-Siergiejko AK, Janowitz T, Beyaz S, Wang G, Xu S, Bialkowska AB, Luo CK, Pin CL, Liang G, Lu X, Wu M, Shroyer KR, Wolff RA, Plunkett W, Ji B, Li Z, Li E, Li X, Yang VW, Logsdon CD, Abbruzzese JL, Lu W. Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet. Gastroenterology 157(5):1413-1428.e11, 2019. e-Pub 2019. PMID: 31352001.
Lai TH, Mitchell S, Wu PJ, Orwick S, Liu C, Ravikrishnan J, Woyach J, Mims A, Plunkett W, Puduvalli VK, Byrd JC, Lapalombella R, Sampath D. HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics. Leuk Lymphoma 60(9):1-4, 2019. e-Pub 2019. PMID: 30773117.
Chen R, Zhu M, Chaudhari RR, Robles O, Chen Y, Skillern W, Qin Q, Wierda WG, Zhang S, Hull KG, Romo D, Plunkett W. Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. Leukemia 33(7):1663-1674, 2019. e-Pub 2019. PMID: 30700841.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. e-Pub 2019. PMID: 31141631.
Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett W. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer 125(10):1665-1673, 2019. e-Pub 2019. PMID: 30668890.
Elsayed AH, Cao X, Crews KR, Gandhi V, Plunkett W, Rubnitz JE, Ribeiro RC, Pounds SB, Lamba JK. Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. Pharmacogenomics 19(14):1101-1110, 2018. e-Pub 2018. PMID: 30088438.
Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2018. PMID: 28718728.
Liu X, Jiang Y, Nowak B, Qiang B, Cheng N, Chen Y, Plunkett W. Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations. Cancer Chemother Pharmacol 81(2):255-267, 2018. e-Pub 2018. PMID: 29189915.
Abo MA, Sasanuma H, Liu X, Rajapakse VN, Huang SY, Kiselev E, Takeda S, Plunkett W, Pommier Y. TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors. Mol Cancer Ther 16(11):2543-2551, 2017. e-Pub 2017. PMID: 28802254.
Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer 123(22):4430-4439, 2017. e-Pub 2017. PMID: 28708931.
Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Vannini I, Redis RS, D'Abundo L, Zhang X, Xiao L, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA. Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res 23(11):2891-2904, 2017. e-Pub 2017. PMID: 27903673.
Bottoni A, Rizzotto L, Lai TH, Liu C, Smith LL, Mantel R, Reiff S, El-Gamal D, Larkin K, Johnson AJ, Lapalombella R, Lehman A, Plunkett W, Byrd JC, Blachly JS, Woyach JA, Sampath D. Targeting BTK through microRNA in chronic lymphocytic leukemia. Blood 128(26):3101-3112, 2016. e-Pub 2016. PMID: 27756747.
Liu X, Jiang Y, Nowak B, Hargis S, Plunkett W. Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC. Mol Cancer Ther 15(10):2302-2313, 2016. e-Pub 2016. PMID: 27474148.
Jiang Y, Chen HC, Su X, Thompson PA, Liu X, Do KA, Wierda W, Keating MJ, Plunkett W. ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2). Blood Cancer J 6(9):e465, 2016. e-Pub 2016. PMID: 27588518.
Lai TH, Ewald B, Zecevic A, Liu C, Sulda M, Papaioannou D, Garzon R, Blachly JS, Plunkett W, Sampath D. HDAC inhibition induces microRNA-182 which targets Rad51 and impairs HR repair to sensitize cells to sapacitabine in acute myelogenous leukemia. Clin Cancer Res 22(14):3537-49, 2016. e-Pub 2016. PMID: 26858310.
Jouanneau M, McClary B, Reyes JC, Chen R, Chen Y, Plunkett W, Cheng X, Milinichik AZ, Albone EF, Liu JO, Romo D. Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe. Bioorg Med Chem Lett 26(8):2092-7, 2016. e-Pub 2016. PMID: 26951751.
Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ. Fludarabine, cyclophosphamide and rituximab achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127(3):303-9, 2016. e-Pub 2016. PMID: 26492934.
Plunkett W. Arginine addiction in AML. Blood 125(26):3971-2, 2015. e-Pub 2015. PMID: 26113532.
Yeh YY, Chen R, Hessler J, Mahoney E, Lehman AM, Heerema NA, Grever MR, Plunkett W, Byrd JC, Johnson AJ. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia. Oncotarget 6(5):2667-79, 2015. e-Pub 2015. PMID: 25596730.
Tam CS, O'Brien S, Plunkett W, Wierda W, Ferrajoli A, Wang X, Do KA, Cortes J, Khouri I, Kantarjian H, Lerner S, Keating MJ. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood 124(20):3059-64, 2014. e-Pub 2014. PMID: 25281606.
Tam C, O'Brien S, Plunkett W, Wierda W, Ferrajoli A, Wang X, K-A D, Cortes J, Khouri I, Kantarjian H Lerner S, Keating M. Life after FCR: outcomes of patients with chonic lymphocytic leukemia who progress after frontline treatment with fludarabine, cyclophosphamide and rituximab. Blood 124(20):3059-3064, 2014. e-Pub 2014.
Tsimberidou AM, Keating MJ, Jabbour EJ, Ravandi-Kashani F, O'Brien S, Estey E, Bekele N, Plunkett W, Kantarjian H, Borthakur G. A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 14(5):395-400.e1, 2014. e-Pub 2014. PMID: 24637132.
Y-Y Y, Chen R, Hessler J, Mahoney E, Lehman AM, Heerema NA, Grever MR, Plunkett W, Byrd JC, Johnson AJ. Up-regulation of CDK9 kinase activity and Mcl-1 stability contribures to the acquired resistance to cyclin-dependent kinase inhitors in leukemia. Oncotarget, 2014. e-Pub 2014.
Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase I and Extension Study of Clofarabine Plus Cyclophosphamide in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 14(3):231-8, 2014. e-Pub 2014. PMID: 24440659.
Gandhi V, Plunkett W, Cortes JE. Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia. Clin Cancer Res 20(7):1735-40, 2014. e-Pub 2014. PMID: 24501394.
Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Varadhachary GR, Ferrari M, Fleming J. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest 124(4):1525-36, 2014. e-Pub 2014. PMID: 24614108.
Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res 37(11):1461-7, 2013. e-Pub 2013. PMID: 23993427.
Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ, Research Consortium CLL. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk 13(5):568-74, 2013. e-Pub 2013. PMID: 23810245.
Cao X, Mitra AK, Pounds S, Crews KR, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics 14(12):1449-66, 2013. e-Pub 2013. PMID: 24024897.
Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol 13(11):1096-104, 2012. e-Pub 2012. PMID: 23075701.
Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 12(4):244-51, 2012. e-Pub 2012. PMID: 22534616.
Liu XJ, Nowak B, Wang YQ, Plunkett W. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks. Chin J Cancer 31(8):373-80, 2012. e-Pub 2012. PMID: 22739266.
Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W, Keating MJ, Huang P. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol 14(3):276-86, 2012. e-Pub 2012. PMID: 22344033.
Carter BZ, Mak DH, Shi Y, Fidler JM, Chen R, Ling X, Plunkett W, Andreeff M. MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Leukemia 26(3):443-50, 2012. e-Pub 2012. PMID: 21904380.
Abdel-Karim I, Plunkett W, O'Brien S, Giles F, Thomas D, Faderl S, Ravandi F, Rios MB, Du M, Schneck KB, Chen VJ, Lin BK, Nicol SJ, Kantarjian HM. A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia. Invest New Drugs 29(2):323-31, 2011. e-Pub 2011. PMID: 20091088.
Chen R, Guo L, Chen Y, Jiang Y, Wierda WG, Plunkett W. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood 117(1):156-64, 2011. e-Pub 2011. PMID: 20971952.
Lamba J, Crews KR, Pounds SB, Cao C, Gandhi V, Plunkett W, Razzouk BI, Lamba V, Baker SD, Raimond, SC, Campana D, C-H P, Downing JR, Rubnitz JE, Ribeiro RC. Identification of predictive markers of cytarabine response in acute myeloid leukemia by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics 12(3):327-39, 2011. e-Pub 2011. PMID: 21449673.
Guo L, Liu X, Jiang Y, Nisikawa K, Plunkett W. DNA-PK and ATM promote cell survival in response to NK314, a topoisomerase IIα inhibitor. Mol Pharmacol 80(2):321-327, 2011. e-Pub 2011. PMID: 21546556.
Zecevic A, Sampath D, Ewald B, Chen R, Wierda W, Plunkett W. Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease. Clin Cancer Res 17(14):4732-4741, 2011. e-Pub 2011. PMID: 21632856.
Mitra AK, Crews CR, Pounds S, Cao X, Feldberg T, Ghodke Y, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi C, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK. Genetic variants in NT5C2 are associated with its expression and cytarabine sensitivity in HapMap cell lines and in AML patients. Pharmacol Exp Ther 339(1):9-23, 2011. e-Pub 2011. PMID: 21712425.
Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S, Tsai CY, Shi X, Schwarzer D, Plunkett W, Aronow B, Gozani O, Fischle W, Hung MC, Patel DJ, Barton MC. TRIM24 links a non-canonical histone signature to breast cancer. Nature 468(7326):927-32, 2010. e-Pub 2010. PMID: 21164480.
Liu X, Wang Y, Benaissa S, Matsuda A, Kantarjian H, Estrov Z, Plunkett W. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. Blood 116(10):1737-46, 2010. e-Pub 2010. PMID: 20479284.
Chen R, Chubb S, Cheng T, Hawtin RE, Gandhi V, Plunkett W. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res 70(16):6587-97, 2010. e-Pub 2010. PMID: 20663900.
Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia S, Negrini M, Wierda W, Kipps TJ, Plunkett W, Coombes KR, Abruzzo LV, Keating MJ, Calin GA. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 116(6):945-52, 2010. e-Pub 2010. PMID: 20393129.
Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, Badros AZ, Popplewell L, Coutre S, Fox JA, Mahadocon K, Chen T, Kegley P, Hoch U, Wierda WG. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 28(18):3015-22, 2010. e-Pub 2010. PMID: 20479412.
Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 28(16):2755-60, 2010. e-Pub 2010. PMID: 20421540.
Dennison JB, Ayres ML, Kaluarachchi K, Plunkett W, Gandhi V. Intracellular succinylation of 8-chloroadenosine and its effect on fumarate levels. J Biol Chem 285(11):8022-30, 2010. e-Pub 2010. PMID: 20064937.
Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Westwood R, Green SR, Chiao JH, Boone PA, Cortes J, Plunkett W. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol 28(2):285-291, 2010. e-Pub 2010. PMID: 19933907.
Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Jäger U, Gandhi V, Kay NE, Plunkett W, Burger JA. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 114(20):4441-50, 2009. e-Pub 2009. PMID: 19762485.
Tsai CY, Ray AS, Tumas DB, Keating MJ, Reiser H, Plunkett W. Targeting DNA Repair in Chronic Lymphocytic Leukemia Cells with a Novel Acyclic Nucleotide Analogue, GS-9219. Clin Cancer Res 15(11):3760-9, 2009. e-Pub 2009. PMID: 19435836.
Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113(19):4637-45, 2009. e-Pub 2009. PMID: 19234140.
Sampath D, Calin GA, Puduvalli VK, Gopisetty G, Taccioli C, Liu CG, Ewald B, Liu C, Keating MJ, Plunkett W. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase, Itch for degradation. Blood 113(16):3744-53, 2009. e-Pub 2009. PMID: 19096009.
Pounds S, Cheng C, Cao X, Crews KR, Plunkett W, Gandhi V, Rubnitz J, Ribeiro RC, Downing JR, Lamba J. PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. Bioinformatics 15(16):2013-9, 2009. e-Pub 2009. PMID: 19528086.
Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933):1457-61, 2009. e-Pub 2009. PMID: 19460966.
Borthakur G, Kantarjian H, Wang X, Plunkett W, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer 113(11):3181-5, 2008. e-Pub 2008. PMID: 18932257.
Chen LS, Plunkett W, Gandhi V. Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues. Leuk Res 32(10):1573-81, 2008. e-Pub 2008. PMID: 18433867.
Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, Chen Z, Pelicano H, Plunkett W, Wierda WG, Keating MJ, Huang P. Effective Elimination of Fludarabine-Resistant CLL Cells by PEITC through a Redox-Mediated Mechanism. Blood 112(5):1912-22, 2008. e-Pub 2008. PMID: 18574029.
Wang Y, Liu X, Matsuda A, Plunkett W. Repair of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair. Cancer Res 68(10):3881-9, 2008. e-Pub 2008. PMID: 18483273.
Reiser H, Wang J, Chong L, Watkins WJ, Ray AS, Shibata R, Birkus G, Cihlar T, Wu S, Li B, Liu X, Henne IN, Wolfgang GH, Desai M, Rhodes GR, Fridland A, Lee WA, Plunkett W, Vail D, Thamm DH, Jeraj R, Tumas DB. GS-9219--A Novel Acyclic Nucleotide Analogue with Potent Antineoplastic Activity in Dogs with Spontaneous Non-Hodgkin's Lymphoma. Clin Cancer Res 14(9):2824-32, 2008. e-Pub 2008. PMID: 18451250.
Gandhi V, Tam C, O'Brien S, Jewell RC, Rodriguez CO, Lerner S, Plunkett W, Keating MJ. Phase I trial of nelarabine in indolent leukemias. J Clin Oncol 26(7):1098-105, 2008. e-Pub 2008. PMID: 18309944.
Liu X, Matsuda A, Plunkett W. Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine. Mol Cancer Ther 7(1):133-42, 2008. e-Pub 2008. PMID: 18202016.
Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26(2):196-203, 2008. e-Pub 2008. PMID: 18182662.
Ewald B, Sampath D, Plunkett W. ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. Cancer Res 68(19):7947-7955, 2008. e-Pub 2008. PMID: 18829552.
Ewald B, Sampath D, Plunkett W. Nucleoside analogues: molecular mechanisms signaling cell death. Oncogene 27(50):6522-6537, 2008. e-Pub 2008. PMID: 18955977.
Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther 323(3):935-45, 2007. e-Pub 2007. PMID: 17855478.
Guo L, Liu X, Nishikawa K, Plunkett, W. Inhibition of topoisomerase IIα and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials. Molec Cancer Therap 6(5):1501-1508, 2007. e-Pub 2007. PMID: 17513599.
Ewald B, Sampath D, Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Molec Cancer Therap 6(4):1239-1248, 2007. e-Pub 2007. PMID: 17706164.
Moufarij MA, Sampath D, Keating MJ, Plunkett W. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood 108:4187-4193, 2006. e-Pub 2006. PMID: 16954499.
Gandhi V, Plunkett W. Clofarabine and nelarabine: Two new purine nucleoside analogs. Curr Opin Oncol 18:584-590, 2006. e-Pub 2006. PMID: 16988579.
Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blast in vitro and during a clinical trial. Blood 107:2517-2524, 2006. e-Pub 2006.
Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 66:10959-10966, 2006. e-Pub 2006. PMID: 17108134.
Pelicano H, Xu RH, Du M, Feng L, Sasaki R, Carew JS, Hu Y, Ramdas L, Hu L, Keating MJ, Zhang W, Plunkett W, Huang P. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol 175:913-923, 2006. e-Pub 2006. PMID: 17158952.
Pelicano H, Carew JS, McQueen TJ, Andreeff M, Plunkett W, Keating MJ, Huang P. Targeting Hsp90 by 17-AAG in leukemia cells: Mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and ara-C. Leukemia 20:610-619, 2006. e-Pub 2006.
Gandhi V, Plunkett W, Bonate PL, Du M, Nowak B, Lerner S, Keating MJ. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: Strategy for treatment. Clin Cancer Res 12:4011-4017, 2006. e-Pub 2006. PMID: 16818700.
Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription independent mechanisms and may overcome ATM-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 108:993-1000, 2006. e-Pub 2006.
Kantarjian H, Beran M, Cortes J, O'Brien S, Giles F, Pierce S, Shan J, Plunkett W, Keating M, Estey E. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 106:1099-1109, 2006. e-Pub 2006.
Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: Mechanism of chronic lymphocytic leukemia cell death. Blood 106:2513-2519, 2005. e-Pub 2005. PMID: 15972445.
Khan SR, Nowak B, Plunkett W, Farquhar D. Bis(pivaloyloxymethyl) thymidine 5'-phosphate is a cell membrane-permeable precursor of thymidine 5'-phosphate in thymidine kinase deficient CCRF CEM cells. Biochem Pharmacol 69:1307-1313, 2005. e-Pub 2005.
Xiong HQ, Plunkett W, Wolff R, Du M, Lenzi R, Abbruzzese JL. A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 55:559-564, 2005. e-Pub 2005. PMID: 15726370.
Gandhi V, Kilpatrick JM, Plunkett W, Ayres M, Harman L, Du M, Bantia S, Davisson J, Wierda WG, Faderl S, Kantarjian H, Thomas D. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood 106:4253-4260, 2005. e-Pub 2005. PMID: 16131572.
Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson E, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 104:541-546, 2005. e-Pub 2005.
Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088, 2005. e-Pub 2005. PMID: 15767648.
Liu X, Guo Y, Li Y, Jiang Y, Chubb S, Azuma A, Huang P, Matsuda A, Hittelman W, Plunkett W. Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation. Cancer Res 65:6874-6881, 2005. e-Pub 2005. PMID: 16061671.
Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105:940-947, 2005. e-Pub 2005. PMID: 15486072.
Bonate PL, Craig A, Gaynon P, Gandhi V, Jeha S, Kadota R, Lam GN, Plunkett W, Razzouk B, Rytting M, Steinherz P, Weitman S. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol 44:1309-1322, 2004. e-Pub 2004. PMID: 15496649.
Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, Rytting M, Brandt M, Keating M, Plunkett W, Kantarjian H. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 103:784-789, 2004. e-Pub 2004. PMID: 14551141.
Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF, Gandhi V. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res 27:1077-1083, 2003. e-Pub 2003. PMID: 12921943.
Gandhi V, Kantarjian H, Faderl S, Bonate P, Du M, Ayres M, Rios MB, Keating MJ, Plunkett W. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 9:6335-6342, 2003. e-Pub 2003. PMID: 14695132.
Rao VA, Plunkett W. Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine. Clin Cancer Res 9:3204-3212, 2003. e-Pub 2003. PMID: 12912974.
Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 21:1167-1173, 2003. e-Pub 2003. PMID: 12637486.
Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 101:4098-4104, 2003. e-Pub 2003. PMID: 12531810.
Yang LY, Jiang H, Rangel KM, Plunkett W. Cisplatin-induced ubiquitination of RNA polymerase II large subunit and suppression of induction by 7-hydroxystaurosporine (UCN-01). Oncol Rep 10:1489-1495, 2003. e-Pub 2003. PMID: 12883729.
Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W, Keating MJ, Huang P. Inhibition of mitochondrial respiration: A novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 278:37832-37839, 2003. e-Pub 2003. PMID: 12853461.
Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408, 2003. e-Pub 2003. PMID: 12885837.
Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O'Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W, Freireich EJ. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102:2379-2386, 2003. e-Pub 2003. PMID: 12791647.
Crews KR, Gandhi V, Srivastava DK, Razzouk BI, Tong X, Behm FG, Plunkett W, Raimondi SC, Pui CH, Rubnitz JE, Stewart CF, Ribeiro RC. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol 20:4217-4224, 2002. e-Pub 2002. PMID: 12377965.
Keating MJ, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M, Lerner S, Kantarjian H. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leukemia Lymphoma 43:1755-1762, 2002. e-Pub 2002. PMID: 12685828.
Gandhi V, Plunkett W, Du M, Ayres M, Estey EH. Prolonged infusion of gemcitabine: Clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol 20:665-673, 2002. e-Pub 2002. PMID: 11821446.
Yamauchi T, Keating MJ, Plunkett W. UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. Mol Cancer Ther 1:287-294, 2002. e-Pub 2002. PMID: 12467224.
Zhou Y, Achanta G, Pelicano H, Gandhi V, Plunkett W, Huang P. Action of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on DNA metabolism: Incorporation, excision, and cellular response. Mol Pharmacol 61:222-229, 2002. e-Pub 2002. PMID: 11752224.
Sampath D, Shi Z, Plunkett W. Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: Dysregulation by 7-hydroxystaurosporine. Mol Pharmacol 62:680-688, 2002. e-Pub 2002. PMID: 12181445.
Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19:3483-3489, 2001. e-Pub 2001. PMID: 11481354.
Azuma A, Huang P, Matsuda A, Plunkett W. Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC). Biochem Pharmacol 61:1497-1507, 2001. e-Pub 2001. PMID: 11377379.
Millikan RE, Plunkett WK, Smith TL, Williams DL, Logothetis CJ. Gemcitabine modulation of alkylator therapy: A phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin. Cancer 92:194-199, 2001. e-Pub 2001. PMID: 11443627.
Azuma A, Huang P, Matsuda A, Plunkett W. 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: A novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. Mol Pharmacol 59:725-731, 2001. e-Pub 2001. PMID: 11259616.
Shi Z, Azuma A, Sampath D, Li YX, Huang P, Plunkett W. S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res 61:1065-1072, 2001. e-Pub 2001. PMID: 11221834.
Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 7:3580-3589, 2001. e-Pub 2001. PMID: 11705880.
Achanta G, Pelicano H, Feng L, Plunkett W, Huang P. Interaction of p53 and DNA-PK in response to nucleoside analogues: Potential role as a sensor complex for DNA damage. Cancer Res 61:8723-8729, 2001. e-Pub 2001. PMID: 11751391.
Gandhi V, Plunkett W, Weller S, Du M, Ayres M, Rodriguez CO, Jr, Ramakrishna P, Rosner GL, Hodge JP, O'Brien S, Keating MJ. Evaluation of the combination of nelarabine and fludarabine in leukemias: Clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol 19:2142-2152, 2001. e-Pub 2001. PMID: 11304766.
Huang P, Sandoval A, Van Den Neste E, Keating MJ, Plunkett W. Inhibition of RNA transcription: A biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia 14:1405-1413, 2000. e-Pub 2000. PMID: 10942236.
Kisor DF, Plunkett W, Kurtzberg J, Mitchell B, Hodge JP, Ernst T, Keating MJ, Gandhi V. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol 18:995-1003, 2000. e-Pub 2000. PMID: 10694549.
Yang LY, Li L, Jiang H, Shen Y, Plunkett W. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 6:773-781, 2000. e-Pub 2000. PMID: 10741696.
Genini D, Budihardjo I, Plunkett W, Wang X, Carrera CJ, Cottam HB, Carson DA, Leoni LM. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J Biol Chem 275:29-34, 2000. e-Pub 2000. PMID: 10617581.
Esteva FJ, Soh LT, Holmes FA, Plunkett W, Meyers CA, Forman AD, Hortobagyi GN. Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemother Pharmacol 46:382-386, 2000. e-Pub 2000. PMID: 11127942.
Rodriguez CO, Jr, Plunkett W, Paff MT, Du M, Nowak B, Ramakrishna P, Keating MJ, Gandhi V. High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatogr B Biomed Sci Appl 745:421-430, 2000. e-Pub 2000. PMID: 11043760.
Feng L, Achanta G, Pelicano H, Zhang W, Plunkett W, Huang P. Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage. Int J Mol Med 5:597-604, 2000. e-Pub 2000. PMID: 10812007.
Sampath D, Plunkett W. The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage. Cancer Res 60:6408-6415, 2000. e-Pub 2000. PMID: 11103806.
Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407:390-395, 2000. e-Pub 2000. PMID: 11014196.
Giles FJ, O'Brien SM, Santini V, Gandhi V, Plunkett W, Seymour JF, Robertson LE, Kantarjian HM, Keating MJ. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leukemia Lymphoma 36:57-65, 1999. e-Pub 1999. PMID: 10613450.
Wilhelm M, O'Brien S, Rios MB, Estey E, Keating MJ, Plunkett W, Sorenson M, Kantarjian HM. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase. Leukemia Lymphoma 34:511-518, 1999. e-Pub 1999. PMID: 10492074.
Milas L, Fujii T, Hunter N, Elshaikh M, Mason K, Plunkett W, Ang KK, Hittelman W. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 59:107-114, 1999. e-Pub 1999. PMID: 9892194.
Consoli U, El-Tounsi I, Sandoval A, Snell V, Kleine HD, Brown W, Robinson JR, DiRaimondo F, Plunkett W, Andreeff M. Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia. Blood 91:1742-1748, 1998. e-Pub 1998. PMID: 9473241.
Touroutoglou N, Gravel D, Raber MN, Plunkett W, Abbruzzese JL. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 9:1003-1008, 1998. e-Pub 1998. PMID: 9818075.
Gandhi V, Plunkett W, Kantarjian H, Talpaz M, Robertson LE, O'Brien S. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. J Clin Oncol 16:2321-2331, 1998. e-Pub 1998. PMID: 9667246.
Gandhi V, Plunkett W, Rodriguez CO, Jr, Nowak BJ, Du M, Ayres M, Kisor DF, Mitchell BS, Kurtzberg J, Keating MJ. Compound GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response. J Clin Oncol 16:3607-3615, 1998. e-Pub 1998. PMID: 9817282.
Li L, Liu X, Glassman AB, Keating MJ, Stros M, Plunkett W, Yang LY. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res 57:1487-1494, 1997. e-Pub 1997. PMID: 9108450.
Gandhi V, Huang P, Chapman AJ, Chen F, Plunkett W. Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences. Clin Cancer Res 3:1347-1355, 1997. e-Pub 1997. PMID: 9815818.
Li L, Keating MJ, Plunkett W, Yang LY. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: Induction of synergistic cytotoxicity independent of reversal of apoptosis resistance. Mol Pharmacol 52:798-806, 1997. e-Pub 1997. PMID: 9351970.
Huang P, Ballal K, Plunkett W. Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis. Cancer Res 57:3407-3414, 1997. e-Pub 1997. PMID: 9270006.
Gandhi V, Estey E, Du M, Keating MJ, Plunkett W. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res 3:1539-1545, 1997. e-Pub 1997. PMID: 9815841.
Iwasaki H, Huang P, Keating MJ, Plunkett W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 90:270-278, 1997. e-Pub 1997. PMID: 9207462.
McConkey DJ, Chandra J, Wright S, Plunkett W, McDonnell TJ, Reed JC, Keating M. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 156:2624-2630, 1996. e-Pub 1996. PMID: 8786328.
Robertson LE, Denny AW, Huh YO, Plunkett W, Keating MJ, Nelson JA. Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine. Cancer Chemother Pharmacol 37:445-450, 1996. e-Pub 1996. PMID: 8599867.
Gandhi V, Legha J, Chen F, Hertel LW, Plunkett W. Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res 56:4453-4459, 1996. e-Pub 1996. PMID: 8813140.
Sandoval A, Consoli U, Plunkett W. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin Cancer Res 2:1731-1741, 1996. e-Pub 1996. PMID: 9816124.
Loughlin S, Gandhi V, Plunkett W, Zwelling LA. The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells. Cancer Chemother Pharmacol 38:261-268, 1996. e-Pub 1996. PMID: 8646801.
Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 87:256-264, 1996. e-Pub 1996. PMID: 8547650.
Kamiya K, Huang P, Plunkett W. Inhibition of the 3' --> 5' exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA. J Biol Chem 271:19428-19435, 1996. e-Pub 1996. PMID: 8702631.
Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 10:1563-1569, 1996. e-Pub 1996. PMID: 8847890.
Seymour JF, Huang P, Plunkett W, Gandhi V. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: Implications for a continuous infusion schedule. Clin Cancer Res 2:653-658, 1996. e-Pub 1996. PMID: 9816215.
Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine. Cancer Res 56:3030-3037, 1996. e-Pub 1996. PMID: 8674058.
Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 10:456-459, 1996. e-Pub 1996. PMID: 8642861.
Gregoire V, Hunter NR, Brock WA, Hittelman WN, Plunkett W, Milas L. Improvement in the therapeutic ratio of radiotherapy for a murine sarcoma by indomethacin plus fludarabine. Radiat Res 146:548-553, 1996. e-Pub 1996. PMID: 8896581.
Xu YZ, Huang P, Plunkett W. Functional compartmentation of dCTP pools. Preferential utilization of salvaged deoxycytidine for DNA repair in human lymphoblasts. J Biol Chem 270:631-637, 1995. e-Pub 1995. PMID: 7822289.
Benvenuto JA, Hittelman WN, Zwelling LA, Plunkett W, Pandita TK, Farquhar D, Newman RA. Biochemical pharmacology of penclomedine (NSC-338720). Biochem Pharmacol 50:1157-1164, 1995. e-Pub 1995. PMID: 7488229.
Huang P, Robertson LE, Wright S, Plunkett W. High molecular weight DNA fragmentation: A critical event in nucleoside analogue-induced apoptosis in leukemia cells. Clin Cancer Res 1:1005-1013, 1995. e-Pub 1995. PMID: 9816073.
Gandhi V, Mineishi S, Huang P, Chapman AJ, Yang Y, Chen F, Nowak B, Chubb S, Hertel LW, Plunkett W. Cytotoxicity, metabolism, and mechanisms of action of 2',2'-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res 55:1517-1524, 1995. e-Pub 1995. PMID: 7533664.
Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res 1:169-178, 1995. e-Pub 1995. PMID: 9815970.
Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36:181-188, 1995. e-Pub 1995. PMID: 7781136.
Gregoire V, Ruifrok AC, Price RE, Brock WA, Hittelman WN, Plunkett WK, Ang KK. Effect of intra-peritoneal fludarabine on rat spinal cord tolerance to fractionated irradiation. Radiother Oncol 36:50-55, 1995. e-Pub 1995. PMID: 8525025.
Yang LY, Li L, Keating MJ, Plunkett W. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol 47:1072-1079, 1995. e-Pub 1995. PMID: 7746274.
Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Plunkett W, Keating MJ. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia 9:1444-1449, 1995. e-Pub 1995. PMID: 7658710.
Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 55:2847-2852, 1995. e-Pub 1995. PMID: 7540950.
Gregoire V, Hunter N, Milas L, Brock WA, Plunkett W, Hittelman WN. Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine. Cancer Res 54:468-474, 1994. e-Pub 1994. PMID: 8275483.
Gandhi V, Robertson LE, Keating MJ, Plunkett W. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: Clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol 34:30-36, 1994. e-Pub 1994. PMID: 8174200.
Ellis AL, Nowak B, Plunkett W, Zwelling LA. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent. Cancer Chemother Pharmacol 34:249-256, 1994. e-Pub 1994. PMID: 8004759.
Gregoire V, Van NT, Stephens LC, Brock WA, Milas L, Plunkett W, Hittelman WN. The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res 54:6201-6209, 1994. e-Pub 1994. PMID: 7954467.
Gregoire V, Hunter N, Brock WA, Milas L, Plunkett W, Hittelman WN. Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single-dose irradiation. Int J Radiat Oncol Biol Phys 30:363-371, 1994. e-Pub 1994. PMID: 7928463.
Lockhart S, Plunkett W, Jeha S, Ramirez I, Zipf T, Cork A, Pinkel D. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia. J Clin Oncol 12:587-595, 1994. e-Pub 1994. PMID: 8120558.
Gandhi V, Du M, Kantarjian HM, Plunkett W. Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia 8:1463-1468, 1994. e-Pub 1994. PMID: 8090026.
Ghaddar HM, Plunkett W, Kantarjian HM, Pierce S, Freireich EJ, Keating MJ, Estey EH. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia 8:1269-1274, 1994. e-Pub 1994. PMID: 8057660.
Robertson LE, Chubb S, Meyn RE, Story M, Ford R, Hittelman WN, Plunkett W. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood 81:143-150, 1993. e-Pub 1993. PMID: 8093345.
Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ, et al. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81:1146-1151, 1993. e-Pub 1993. PMID: 8382970.
Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leukemia Lymphoma 9:343-350, 1993. e-Pub 1993. PMID: 8394169.
Kemena A, O'Brien S, Kantarjian H, Robertson L, Koller C, Beran M, Estey E, Plunkett W, Lerner S, Keating MJ. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leukemia Lymphoma 10:187-193, 1993. e-Pub 1993. PMID: 8220117.
Gandhi V, Kemena A, Keating MJ, Plunkett W. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma 10:49-56, 1993. e-Pub 1993. PMID: 8374523.
Suki S, Kantarjian H, Gandhi V, Estey E, O'Brien S, Beran M, Rios MB, Plunkett W, Keating M. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer 72:2155-2160, 1993. e-Pub 1993. PMID: 8374873.
Keating MJ, O'Brien S, Kantarjian H, Plunkett W, Estey E, Koller C, Beran M, Freireich EJ. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81:2878-2884, 1993. e-Pub 1993. PMID: 8499626.
Xu YZ, Plunkett W. Regulation of thymidine kinase and thymidylate synthase in intact human lymphoblast CCRF-CEM cells. J Biol Chem 268:22363-22368, 1993. e-Pub 1993. PMID: 8226747.
Robertson LE, Hall R, Keating MJ, Estey E, Kantarjian HM, McLaughlin P, Hagemeister FB, Plunkett W. High-dose cytosine arabinoside in chronic lymphocytic leukemia: A clinical and pharmacologic analysis. Leukemia Lymphoma 10:43-48, 1993. e-Pub 1993. PMID: 8374522.
Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11:116-124, 1993. e-Pub 1993. PMID: 8418222.
Xu YZ, Plunkett W. Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine. Biochem Pharmacol 44:1819-1827, 1992. e-Pub 1992. PMID: 1449536.
Gandhi V, Plunkett W. Cell cycle-specific metabolism of arabinosylnucleosides in K562 human leukemia cells. Cancer Chemother Pharmacol 31:11-17, 1992. e-Pub 1992. PMID: 1458554.
Huang P, Plunkett W. A quantitative assay for fragmented DNA in apoptotic cells. Anal Biochem 207:163-167, 1992. e-Pub 1992. PMID: 1489090.
Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406-413, 1992. e-Pub 1992. PMID: 1740680.
Gandhi V, Kemena A, Keating MJ, Plunkett W. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 52:897-903, 1992. e-Pub 1992. PMID: 1737352.
Yang SW, Huang P, Plunkett W, Becker FF, Chan JY. Dual mode of inhibition of purified DNA ligase I from human cells by 9-beta-D-arabinofuranosyl-2-fluoroadenine triphosphate. J Biol Chem 267:2345-2349, 1992. e-Pub 1992. PMID: 1310314.
Huang P, Farquhar D, Plunkett W. Selective action of 2',3'-didehydro-2',3'-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases. J Biol Chem 267:2817-2822, 1992. e-Pub 1992. PMID: 1370834.
Kemena A, Gandhi V, Shewach DS, Keating M, Plunkett W. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy. Cancer Chemother Pharmacol 31:193-199, 1992. e-Pub 1992. PMID: 1464155.
Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: A mechanism of self-potentiation. Cancer Res 52:533-539, 1992. e-Pub 1992. PMID: 1732039.
Sastry JK, Nehete PN, Khan S, Nowak BJ, Plunkett W, Arlinghaus RB, Farquhar D. Membrane-permeable dideoxyuridine 5'-monophosphate analogue inhibits human immunodeficiency virus infection. Mol Pharmacol 41:441-445, 1992. e-Pub 1992. PMID: 1372082.
Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F, Jr, Rodriguez MA, Plunkett WK, Keating MJ. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 10:790-794, 1992. e-Pub 1992. PMID: 1373760.
Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W. A phase I clinical, plasma, and cellular pharmacology study of 2',2'-difluorodeoxycytidine. J. Clin. Oncol 9:491-498, 1991. e-Pub 1991.
Kemena A, Fernandez M, Bauman J, Keating M, Plunkett W. A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids. Clin Chim Acta 200:95-106, 1991. e-Pub 1991. PMID: 1723357.
Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27:258-262, 1991. e-Pub 1991. PMID: 1998982.
Damon LE, Plunkett W, Linker CA. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res 51:4141-4145, 1991. e-Pub 1991. PMID: 1868435.
Huang P, Plunkett W. Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism. Mol Pharmacol 39:449-455, 1991. e-Pub 1991. PMID: 1708088.
Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117, 1991. e-Pub 1991. PMID: 1718594.
Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W. Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 50:6823-6826, 1990. e-Pub 1990. PMID: 2208147.
Gandhi V, Plunkett W. Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 50:3675-3680, 1990. e-Pub 1990. PMID: 2340517.
Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. Mol Pharmacol 38:567-572, 1990. e-Pub 1990. PMID: 2233693.
Estey EH, Keating MJ, McCredie KB, Freireich EJ, Plunkett W. Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia 4:95-99, 1990. e-Pub 1990. PMID: 2304361.
Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem 265:16617-16625, 1990. e-Pub 1990. PMID: 1697861.
Huang P, Farquhar D, Plunkett W. Selective action of 3'-azido-3'-deoxythymidine 5'-triphosphate on viral reverse transcriptases and human DNA polymerases. J Biol Chem 265:11914-11918, 1990. e-Pub 1990. PMID: 1694849.
Gandhi V, Nowak B, Keating MJ, Plunkett W. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: Implications for combination therapy. Blood 74:2070-2075, 1989. e-Pub 1989. PMID: 2478221.
Huang P, Siciliano MJ, Plunkett W. Gene deletion, a mechanism of induced mutation by arabinosyl nucleosides. Mutat Res 210:291-301, 1989. e-Pub 1989. PMID: 2911256.
Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74:19-25, 1989. e-Pub 1989. PMID: 2473795.
Gandhi V, Plunkett W. Interaction of arabinosyl nucleotides in K562 human leukemia cells. Biochem Pharmacol 38:3551-3558, 1989. e-Pub 1989. PMID: 2479383.
Heinemann V, Plunkett W. Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine. Biochem Pharmacol 38:4115-4121, 1989. e-Pub 1989. PMID: 2688654.
Heinemann V, Murray D, Walters R, Meyn RE, Plunkett W. Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemother Pharmacol 22:205-210, 1988. e-Pub 1988. PMID: 3165725.
Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 48:329-334, 1988. e-Pub 1988. PMID: 3335008.
Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 48:4024-4031, 1988. e-Pub 1988. PMID: 3383195.
Walters RS, Kantarjian HM, Keating MJ, Plunkett W, Estey EH, Andersson B, Beran M, McCredie KB, Freireich EJ. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer 62:677-682, 1988. e-Pub 1988. PMID: 3165047.
Estey E, Plunkett W, Dixon D, Keating M, McCredie K, Freireich EJ. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1:580-583, 1987. e-Pub 1987. PMID: 3669771.
Huang P, Plunkett W. Phosphorolytic cleavage of 2-fluoroadenine from 9-beta-D-arabinofuranosyl-2-fluoroadenine by Escherichia coli. A pathway for 2-fluoro-ATP production. Biochem Pharmacol 36:2945-2950, 1987. e-Pub 1987. PMID: 3307790.
Danhauser L, Plunkett W, Liliemark J, Gandhi V, Iacoboni S, Keating M. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. Leukemia 1:638-643, 1987. e-Pub 1987. PMID: 3478543.
Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res 47:3005-3011, 1987. e-Pub 1987. PMID: 3471322.
Gandhi V, Danhauser L, Plunkett W. Separation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography. J Chromatogr 413:293-299, 1987. e-Pub 1987. PMID: 3558682.
Plunkett W, Nowak B, Keating MJ. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. Cancer Treat Rep 71:479-483, 1987. e-Pub 1987. PMID: 3567973.
Danhauser L, Plunkett W, Keating M, Cabanillas F. 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol 18:145-152, 1986. e-Pub 1986. PMID: 2431803.
Liliemark JO, Plunkett W. Regulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in human leukemia cells by deoxycytidine 5'-triphosphate. Cancer Res 46:1079-1083, 1986. e-Pub 1986. PMID: 3484676.
Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 81:387-394, 1986. e-Pub 1986. PMID: 3463209.
Shewach DS, Plunkett W. Cellular retention of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and the pattern of recovery of DNA synthesis in Chinese hamster ovary cells. Cancer Res 46:1581-1584, 1986. e-Pub 1986. PMID: 2418951.
Iacoboni SJ, Plunkett W, Kantarjian HM, Estey E, Keating MJ, McCredie KB, Freireich EJ. High-dose cytosine arabinoside: Treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 4:1079-1088, 1986. e-Pub 1986. PMID: 3459811.
Saunders PP, Tan MT, Spindler CD, Robins RK, Plunkett W. 3-Deazaguanosine is metabolized to the triphosphate derivative in Chinese hamster cells deficient in hypoxanthine-guanine phosphoribosyltransferase. J Biol Chem 261:6416-6422, 1986. e-Pub 1986. PMID: 3700397.
Liliemark JO, Plunkett W, Dixon DO. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res 45:5952-5957, 1985. e-Pub 1985. PMID: 4053067.
Kuo MT, Plunkett W. Nick-translation of metaphase chromosomes: in vitro labeling of nuclease-hypersensitive regions in chromosomes. Proc Natl Acad Sci USA 82:854-858, 1985. e-Pub 1985. PMID: 3856236.
Trkula D, Otsuka H, Plunkett W. Resistance to mutagenesis of cells biochemically transformed by herpesvirus DNA fragments. Biochem Biophys Res Commun 133:1064-1071, 1985. e-Pub 1985. PMID: 3002361.
Kantarjian H, Dreicer R, Barlogie B, Plunkett W, Alexanian R. High-dose cytosine arabinoside in multiple myeloma. Eur J Cancer Clin Oncol 20:227-231, 1984. e-Pub 1984. PMID: 6538488.
Avramis VI, Plunkett W. Metabolism of 9-beta-D-arabinosyl-2-fluoroadenine-5'-phosphate by mice bearing P388 leukemia. Cancer Drug Deliv 1:1-10, 1983. e-Pub 1983. PMID: 6085754.
Avramis VI, Plunkett W. 2-fluoro-ATP: A toxic metabolite of 9-beta-D-arabinosyl-2-fluoroadenine. Biochem Biophys Res Commun 113:35-43, 1983. e-Pub 1983. PMID: 6860342.
Kantarjian H, Barlogie B, Plunkett W, Velasquez W, McLaughlin P, Riggs S, Cabanillas F. High-dose cytosine arabinoside in non-Hodgkin's lymphoma. J Clin Oncol 1:689-694, 1983. e-Pub 1983. PMID: 6366130.
Harris BA, Plunkett W. Termination of RNA by nucleotides of 9-beta-D-xylofuranosyladenine. Biochem Biophys Res Commun 106:500-505, 1982. e-Pub 1982. PMID: 6179518.
Moore EC, Friedman J, Valdivieso M, Plunkett W, Marti JR, Russ J, Loo TL. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate. Biochem Pharmacol 31:3317-3321, 1982. e-Pub 1982. PMID: 7150358.
Shewach DS, Plunkett W. Effect of 2'-deoxycoformycin on the inhibition of deoxyribonucleic acid synthesis by 9-beta-D-arabinofuranosyladenine 5'-triphosphate. Biochem Pharmacol 31:2103-2109, 1982. e-Pub 1982. PMID: 6180754.
Shewach DS, Plunkett W. Correlation of cytotoxicity with total intracellular exposure to 9-beta-D-arabinofuranosyladenine 5'-triphosphate. Cancer Res 42:3637-3641, 1982. e-Pub 1982. PMID: 6179604.
Avramis VI, Plunkett W. Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388. Cancer Res 42:2587-2591, 1982. e-Pub 1982. PMID: 7083151.
Barlogie B, Plunkett W, Raber M, Latreille J, Keating M, McCredie K. In vivo cellular kinetic and pharmacological studies of 1-beta-D-arabinofuranosylcytosine and 3-deazauridine chemotherapy for relapsing acute leukemia. Cancer Res 41:1227-1235, 1981. e-Pub 1981. PMID: 7459863.
Harris BA, Plunkett W. Biochemical basis for the cytotoxicity of 9-beta-D-xylofuranosyladenine in Chinese hamster ovary cells. Cancer Res 41:1039-1044, 1981. e-Pub 1981. PMID: 6161693.
Harris BA, Saunders PP, Plunkett W. Metabolism of 9-beta-D-xylofuranosyladenine by the Chinese hamster ovary cell. Mol Pharmacol 20:200-205, 1981. e-Pub 1981. PMID: 6270533.
Plunkett W, Hug V, Keating MJ, Chubb S. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res 40:588-591, 1980. e-Pub 1980. PMID: 6937239.
Plunkett W, Chubb S, Barlogie B. Simultaneous determination of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 3-deazauridine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography. J Chromatogr 221:425-430, 1980. e-Pub 1980. PMID: 6938519.
Valdivieso M, Moore EC, Burgess AM, Marti JR, Russ J, Plunkett W, Loo TL, Bodey GP, Freireich EJ. Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA). Cancer Treat Rep 64:285-292, 1980. e-Pub 1980. PMID: 7407763.
Plunkett W, Chubb S, Alexander L, Montgomery JA. Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res 40:2349-2355, 1980. e-Pub 1980. PMID: 6966966.
Stewart DJ, Benvenuto J, Leavens M, Hall S, Benjamin RS, Plunkett W, McCredie KB, Burgess MA, Bodey GP, Loo TL. Central nervous system pharmacology of 3-deazauridine in man. Cancer Res 39:4119-4122, 1979. e-Pub 1979.
Plunkett W, Benvenuto JA, Stewart DJ, Loo TL. High-pressure liquid chromatographic analysis of 3-deazauridine-5'-triphosphate in human cancer cells. Cancer Treat Rep 63:415-420, 1979. e-Pub 1979. PMID: 284846.
Plunkett W, Alexander L, Chubb S, Loo TL. Biochemical basis of the increased activity of 9-beta-D-arabinofuranosyladenine in the presence of inhibitors of adenosine deaminase. Cancer Res 39:3655-3660, 1979. e-Pub 1979. PMID: 476690.
Plunkett W, Alexander L, Chubb S, Loo TL. Comparison of the activity of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine in vivo. Biochem Pharmacol 28:201-206, 1979. e-Pub 1979. PMID: 426835.
Shewach DS, Plunkett W. Effect of 2'-deoxycoformycin on the biologic half-life of 9-beta-D-arabinofuranosyladenine 5'-triphosphate in CHO cells. Biochem Pharmacol 28:2401-2404, 1979. e-Pub 1979. PMID: 91375.
Plunkett W, Moner JG. UMP pyrophosphorylase of Tetrahymena pyriformis. Partial purification and properties. Arch Biochem Biophys 187:264-271, 1978. e-Pub 1978. PMID: 26316.
Plunkett W, Cohen SS. Penetration of mouse fibroblasts by 2'-deoxyadenosine 5'-phosphate and incorporation of the nucleotide into DNA. J Cell Physiol 91:261-270, 1977. e-Pub 1977. PMID: 558986.
Plunkett W, Cohen SS. Metabolism of 9-beta-D-arabinofuranosyladenine by mouse fibroblasts. Cancer Res 35:415-422, 1975. e-Pub 1975.
Plunkett W, Cohen SS. Two approaches that increase the activity of analogs of adenine nucleosides in animal cells. Cancer Res 35:1547-1554, 1975. e-Pub 1975. PMID: 1079475.
Plunkett W, Lapi L, Ortiz PJ, Cohen SS. Penetration of mouse fibroblasts by the 5'-phosphate of 9-beta-D-arabinofuranosyladenine and incorporation of the nucleotide into DNA. Proc Natl Acad Sci USA 71:73-77, 1974. e-Pub 1974. PMID: 4359332.
Longo FJ, Plunkett W. The onset of DNA synthesis and its relation to morphogenetic events of the pronuclei in activated eggs of the sea urchin, Arbacia punctulata. Dev Biol 30:56-67, 1973. e-Pub 1973. PMID: 4735369.
Plunkett W, Moner JG. The role of uridine-cytidine kinase in the regulation of pyrimidine ribonucleotide synthesis in Tetrahymena pyriformis GL. Biochim Biophys Acta 250:92-102, 1971. e-Pub 1971. PMID: 4258867.

Invited Articles

Chen R, Plunkett W. Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 23(1):155-66, 2010. e-Pub 2010. PMID: 20620979.
Ghanem H, Jabbour E, Faderl S, Gandhi V, Plunkett W, Kantarjian H. Clofarabine in leukemia. Expert Rev Hematol 3(1):15-22, 2010. e-Pub 2010. PMID: 21082931.
Sampath D, Plunkett W. The Role of DNa Repair in CLL Phathogenesis and Chemotherapy Resistance. Current Oncol Repts 9(5):361-367, 2007. e-Pub 2007. PMID: 17706164.
Tili E, J-J M, Gandhi V, Plunkett W, Sampath D, Calin G. miRNAs and their potential for use against cancer and other diseases. Future Medicine 3(5):521-537, 2007. e-Pub 2007.
Plunkett W. Rationale for the design of combination therapies that are active in T-cell lymphomas. Haematologica Reports 2:83-86, 2006. e-Pub 2006.
Gandhi V, Plunkett W. Clofarabine and Nelarabine: Two new purine nucleoside analogs. Current Opinion in Oncology 18:584-590, 2006. e-Pub 2006.
Chen R, Plunkett W. Sequential blockade of oncogenic kinases. American Association for Cancer Research Annual Meeting Education Book 348:344, 2005. e-Pub 2005.
Cooper T, Kantarjian H, Plunkett W, Gandhi V. Clofarabine in adult acute leukemias: Clinical success and pharmacokinetics. Nucleosides Nucleotides Nucleic Acids 23:1417-1423, 2004. e-Pub 2004. PMID: 15571270.
Sampath D, Plunkett W. Design of new anticancer therapies targeting cell cycle checkpoint pathways. Current Opinion in Oncology 13:484-490, 2001. e-Pub 2001. PMID: 11673689.
Plunkett W. DNA repair: Extending the range of cycle-specific drugs in indolent diseases. American Society of Hematology Education Program Book:470-475, 1999. e-Pub 1999.
Heinemann V, Estey E, Keating MJ, Plunkett W. Patient-specific dose rate for continuous infusion high-dose arabinosylcytosine in relapsed acute myelogenous leukemia. Clin. Oncol 7:622-628, 1999. e-Pub 1999.
Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J. Clin. Oncol 9:491-498, 1999. e-Pub 1999.
Plunkett W, Kawai Y, Sandoval A, O'Brien S, Keating MJ, Huang P, Gandhi V. Mechanism-based rationales for combination therapies of lymphoid malignancies. Haematologica 84:73-77, 1999. e-Pub 1999.
Azuma A, Huang P, Matsuda A, Plunkett W. Intracellular metabolism and action of an antitumor nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine (CNDAC). Nucleosides & Nucleotides 16:1037-1039, 1997. e-Pub 1997.
Plunkett W, Huang P, Gandhi V. Gemcitabine: Actions and interactions. Nucleosides & Nucleotides 16:1261-1270, 1997. e-Pub 1997.
Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol 23:3-15, 1996. e-Pub 1996. PMID: 8893876.
Binet JL, Plunkett W, Robertson B, Merle-Beral H, Mentz F, Hoffbrand AV, Panayiotidis P. What does apoptosis mean in CLL?. Leukemia Lymphoma 22 Suppl 2:47-52, 1996. e-Pub 1996. PMID: 9021708.
Gandhi V, Estey EH, Keating MJ, Plunkett W. Intracellular pharmacodynamics in leukemia therapy. Rinsho Ketsueki 37:369-379, 1996. e-Pub 1996. PMID: 8691580.
Plunkett W, Gandhi V. Pharmacology of purine nucleoside analogues. Hematol Cell Therapy 38 Suppl 2:S67-74, 1996. e-Pub 1996. PMID: 9137959.
Keating MJ, O'Brien S, McLaughlin P, Dimopoulos M, Gandhi V, Plunkett W, Lerner S, Kantarjian H, Estey E. Clinical experience with fludarabine in hemato-oncology. Hematol Cell Therapy 38 Suppl 2:S83-91, 1996. e-Pub 1996. PMID: 9137961.
Plunkett W, Begleiter A, Liliemark JO, Reed JC. Why do drugs work in CLL?. Leukemia Lymphoma 22 Suppl 2:1-11, 1996. e-Pub 1996. PMID: 9021705.
Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3-10, 1995. e-Pub 1995. PMID: 7481842.
Huang P, Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol 22:19-25, 1995. e-Pub 1995. PMID: 7481840.
Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 6 Suppl 6:7-13, 1995. e-Pub 1995. PMID: 8718419.
Heinemann V, Schulz L, Issels RD, Plunkett W. Gemcitabine: A modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol 22:11-18, 1995. e-Pub 1995. PMID: 7481839.
Peters GJ, Plunkett W. Introduction: Gemcitabine--status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog. Semin Oncol 22:1-2, 1995. e-Pub 1995.
Gandhi V, Mineishi S, Huang P, Yang Y, Chubb S, Chapman AJ, Nowak BJ, Hertel LW, Plunkett W. Difluorodeoxyguanosine: Cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Semin Oncol 22:61-67, 1995. e-Pub 1995. PMID: 7481847.
Wright SJ, Robertson LE, O'Brien S, Plunkett W, Keating MJ. The role of fludarabine in hematological malignancies. Blood Rev 8:125-134, 1994. e-Pub 1994. PMID: 7819814.
Keating MJ, McLaughlin P, Plunkett W, Robertson LE, O'Brien S, Gandhi V, Gregoire V, Yang L, Cabanillas F. Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol 5 Suppl 2:79-83, 1994. e-Pub 1994. PMID: 8204523.
Keating MJ, Estey E, O'Brien S, Kantarjian H, Robertson LE, Plunkett W. Clinical experience with fludarabine in leukaemia. Drugs 47 Suppl 6:39-49, 1994. e-Pub 1994. PMID: 7525188.
Keating MJ, O'Brien S, Plunkett W, Robertson LE, Gandhi V, Estey E, Dimopoulos M, Cabanillas F, Kemena A, Kantarjian H. Fludarabine phosphate: A new active agent in hematologic malignancies. Semin Hematol 31:28-39, 1994. e-Pub 1994. PMID: 7510070.
Robertson LE, Huang P, Keating MJ, Plunkett W. Apoptosis in chronic lymphocytic leukemia. Apoptosis in chronic lymphocytic leukemia 46:130-135, 1994. e-Pub 1994.
Gandhi V, Huang P, Plunkett W. Fludarabine inhibits DNA replication: A rationale for its use in the treatment of acute leukemias. Leukemia Lymphoma 14 Suppl 2:3-9, 1994. e-Pub 1994. PMID: 7881348.
Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Li YY, Gandhi V, Estey, E, Plunkett, W. The expanding role of fludarabine in hematologic malignancies. Leukemia Lymphoma 14 Suppl 2:11-16, 1994. e-Pub 1994. PMID: 7533576.
Plunkett W, Gandhi V. Cellular pharmacodynamics as a guide to leukemia therapy. Cancer Bull 46:8-14, 1994. e-Pub 1994.
Plunkett W, Gandhi V. Evolution of the arabinosides and the pharmacology of fludarabine. Drugs 47 Suppl 6:30-38, 1994. e-Pub 1994. PMID: 7525187.
Plunkett W, Gandhi V, Huang P, Robertson LE, Yang LY, Gregoire V, Estey E, Keating MJ. Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 20:2-12, 1993. e-Pub 1993. PMID: 8235690.
Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Yang LY, Gandhi V, et al. New initiatives with fludarabine monophosphate in hematologic malignancies. Semin Oncol 20:13-20, 1993. e-Pub 1993. PMID: 7694371.
Gandhi V, Estey E, Keating MJ, Plunkett W. Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leukemia Lymphoma 10 Suppl:109-114, 1993. e-Pub 1993. PMID: 8481660.
Estey EH, Plunkett W, Kantarjian H, Rios MB, Keating MJ. Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): Confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C. Leukemia Lymphoma 10 Suppl:115-121, 1993. e-Pub 1993. PMID: 8481661.
Plunkett W, Gandhi V. Cellular pharmacodynamics of anticancer drugs. Semin Oncol 20:50-63, 1993. e-Pub 1993. PMID: 8475410.
Robertson LE, Plunkett W. Apoptotic cell death in chronic lymphocytic leukemia. Leukemia Lymphoma 11 Suppl 2:71-74, 1993. e-Pub 1993. PMID: 8124235.
Plunkett W. Pharmacology, cellular interactions, and mode of action of nucleoside analogs. Advances in Leukemia and Lymphoma 3:3-4, 1992. e-Pub 1992.
Plunkett W, Gandhi V. Pharmacokinetics of arabinosylcytosine. Infusional Chemotherapy 2:169-176, 1992. e-Pub 1992.
Keating MJ, O'Brien S, Robertson LE, Plunkett W, Kantarjian H, Koller C. New drugs in the treatment of chronic lymphocytic leukemia. Leukemia 6:140-141, 1992. e-Pub 1992.
Plunkett W, Saunders PP. Metabolism and action of purine nucleoside analogs. Pharmacol Ther 49:239-268, 1991. e-Pub 1991. PMID: 1675805.
Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Semin Oncol 17:3-17, 1990. e-Pub 1990. PMID: 1699280.
Hertel LW, Grossman CS, Kroin JS, Mineishi S, Chubb S, Nowak B, Plunkett W. Synthesis, cytotoxicity and metabolism of the 2',2'-difluoro-analogs of deoxyadenosine (dFdA) and deoxyguanosine (dFdG). Nucleosides and Nucleotides 8:951-955, 1989. e-Pub 1989.
Plunkett W, Gandhi V, Chubb S, Nowak B, Heinemann V, Mineishi S, Sen A, Hertel LW, Grindey GB. 2',2'-Difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells. Nucleosides and Nucleotides 8:775-785, 1989. e-Pub 1989.
Estey E, Keating MJ, Plunkett W, McCredie KB, Freireich EJ. Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia. Semin Oncol 14:58-63, 1987. e-Pub 1987. PMID: 3473684.
Plunkett W, Liliemark JO, Estey E, Keating MJ. Saturation of ara-CTP accumulation during high-dose ara-C therapy: Pharmacologic rationale for intermediate-dose ara-C. Semin Oncol 14:159-166, 1987. e-Pub 1987. PMID: 3589690.
Plunkett W, Iacoboni S, Keating MJ. Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine. Scand J Haematol Suppl 44:51-59, 1986. e-Pub 1986. PMID: 3457439.
Plunkett, W, Keating MJ. Pharmacologically directed chemotherapy: A rational approach towards antitumor drug administration. Cancer Bulletin 37:196-202, 1985. e-Pub 1985.
Keating MJ, Estey E, Plunkett W, Iacoboni S, Walters R, Kantarjian H, Andersson B, Beran M, McCredie KB, Freireich EJ. Evolution of clinical studies with high-dose cytosine arabinoside at the M. D. Anderson Hospital. Semin Oncol 12:98-104, 1985. e-Pub 1985. PMID: 3859935.
Plunkett W. Inhibition of adenosine deaminase to increase the antitumor activity of adenine nucleoside analogues. Ann N Y Acad Sci 451:150-159, 1985. e-Pub 1985. PMID: 3907452.
Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ. Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 12:20-30, 1985. e-Pub 1985. PMID: 4012338.
Plunkett W, Feun LG, Benjamin RS, Keating MJ, Freireich EJ. Modulation of arabinosyladenine metabolism by 2'-deoxycoformycin for the therapy of acute leukemia. Cancer Treat. Symp 2:23-27, 1984. e-Pub 1984.
Plunkett W. The use of high-pressure liquid chromatography in research on nucleoside analogs. Adv. in Chromatogr 16:211-248, 1978. e-Pub 1978.
Plunkett W, Cohen SS. Increased toxicity of 9-beta-D-arabinofuranosyladenine in the presence of an inhibitor of adenosine deaminase. Ann N Y Acad Sci 284:91-102, 1977. e-Pub 1977. PMID: 280161.
Cohen SS, Plunkett W. The utilization of nucleotides by animal cells. Ann N Y Acad Sci 255:269-286, 1975. e-Pub 1975. PMID: 1059361.

Manuals, Teaching Aids, Other Teaching Publications

Plunkett W. Apoptosis. The story of suicide in the cell. Oxford, 1995.

Editorials

Claxton DF, Plunkett W, Andreeff M, Deisseroth AB. Retinoids and cancer therapy. J Natl Cancer Inst 84:1306-1307, 1992.

Abstracts

Chen R, Chen Y, Green SR, Wierda WG, Plunkett W. A novel derivative of the Cdk inhibitor roscovitine that induces apoptosis in CLL and overcomes stromal cell-mediated protection. Proc AACR 51, 2010. e-Pub 2010.
Liu X, Matsuda A, Plunkett W. DNA strand breaks induced by 2’-C-cyano-2’-deoxy-nucleoside analogs are repaired by homologous recombination. Proc AACR 51, 2010. e-Pub 2010.
Zecevic A, Ewald B, Sampath D, Wierda W, Plunkett W. Mechanism of fludarabine and oxaliplatin combined activity depends on the activity of XPF endonuclease. Proc AACR 51, 2010. e-Pub 2010.
A-M T, Wierda W, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Smith S, Jalayer A, Kantarjian HM, Keating M. Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy Induces High Response Rates in Agressive Chronic Lymphocytic Leukemia (CLL) and Richter's Syndrome (RS). Blood (ASH) 114, 2009. e-Pub 2009.
Lamba JK, Mitra A, Crews K, Pounds S, Cao X, Gandhi V, Plunkett W, Rubnitz J, Ribeiro RC. 5'Nucleotidase (NT5C2) Genotype Influences Leukemic Blast Concentration of Ara-CTP in Pediatric Patients with Acute Myeloid Leukemia. Blood (ASH) 114, 2009. e-Pub 2009.
Chen R, Chubb S, Cheng T, Hawtin RE, Fox JA, Plunkett W. SNS-032 reduced the expression of cyclin D1 and Mcl-1 and inhibited survival in mantle cell lymphoma cell lines. Proc AACR 50, 2009. e-Pub 2009.
Liu X, Matsuda A, Plunkett W. DNA strand breaks induced by the nucleoside analogue CNDAG are repaired by homologous recombination. Proc AACR 50, 2009. e-Pub 2009.
Ewald B, Sampath D, Zecevic A, A-M T, Wierda WG, Plunkett W. Fludarabine and ara-C increase oxaliplatin-induced DNA damage and cytotoxicity in chronic lymphocytic leukemia. Proc AACR 50, 2009. e-Pub 2009.
Lamba JK, Crews K, Pounds S, Cao X, Gandhi V, Plunkett W, Baker SD, C-H P, Campana D, Downing JR, Rubnitz J, Ribeiro RC. Gene Expression Patterns Associated with Cytarabine Pharmacology and Outcome in Pediatric Acute Myeloid Leukemia. Blood (ASH) 114, 2009. e-Pub 2009.
Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes J, O'Brien S, Gandhi V, Plunkett W, Byrd AL, Kwari M, Kantarjian H. Oral Clofarabine in the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome. Blood (ASH) 114, 2009. e-Pub 2009.
Zecevic A, Ewald B, Sampath D, Wierda W, Plunkett W. Fludarabine blocks DNA repair after oxaliplatin exposure producing DNA damage and cell death. Proc AACR 50, 2009. e-Pub 2009.
Guo L, Chen R, Wierda WG, Plunkett W. Homoharringtonine downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia cells. Proc AACR 50, 2009. e-Pub 2009.
Lamba J, Crews K, Puonds S, Cao X, Baker S, Gandhi V, Plunkett W, Downing J, Rubnitz J, Ribeiro RC. Gene expression profiling of acute myeloid leukemia shows therapeutically meaningful patterns of association with Ara-CTP pharmacokinetics and pharmacodynamics. Blood/ASH 112(11):215, 2008. e-Pub 2008.
Ravandi F, Sampath D, Plunkett W, Williams B, Burton M Verstovsek S, Faderl S, Garica-Manero G, Sebti S, Kantarjian H, Lancet J. Phase I study of the Akt-Inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancy. Blood/ASH 112(11):1026-1027, 2008. e-Pub 2008.
Wierda W, Chen R, Plunkett W, Coutre S, Badros A, Popplewell L, Siegel D, Sinha R, Harvey D, Fox J, Mahadocon K, Kegley P, Bolton M G. A phase I trial od SNS-032, a potent and specific CDK 2, 7 and 9 inhibitor, in chronic lymphocytic leukemia and multiple myeloma. Blood/ASH 112(11):1090, 2008. e-Pub 2008.
Faderl S, Garcia-Manero G, Ravandi F, Bortjakur G, Estrov Z, Thomas D A, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian H. Oral (po) and intravenous (iv) clofarabine for patients (pts) with myelodysplastic syndrome (MDS). Blood/ASH 112(11):89, 2008. e-Pub 2008.
Sampath D, Calin G, Pudavalli V, Taccioli C, Ewald B, Keating MJ, Plunkett W. MicroRNA 106b targets the ubiquitin ligase ITCH to enable the p73 apoptotic response in chronic lymphocytic leukemia. Proc AACR 49:557, 2008. e-Pub 2008.
Tsai C, Ray A, Tumas D, Keating M, Reiser H, Plunkett W. Targeting DNA repair in Chronic lymphocytic leukemia cells with the DNA chain terminator, GS-9219. Proc AACR 49:781, 2008. e-Pub 2008.
Guo L, Liu X, Nishikawa K, Plunkett W. ATM and DNA-PK play important roles in cell survivial in response to a DNA intercalator, NK134. Proc AACR 49:151, 2008. e-Pub 2008.
Wang Y, x L, Matsuda A, Plunkett W. Repair of DNA single-strand breaks induced by 2'-C-Cyano-2'-deoxy-1-β-D-arabino-pentofuranosylcytosine through the transcription-coupled nucleotide excision repair. Proc AACR 49:607, 2008. e-Pub 2008.
Ewald B, Sampath D, Plunkett W. The DNA damage repair molecules, ATM and the Mre11-Rad50-Nbs1 complez, contribute to resitatnce to nucleoside analogue-induced cell death. Proc AACR 49:155, 2008. e-Pub 2008.
Segal D, Michaels S, Craig A, Plunkett W, Brown D. Analysis of Bcl-2 family protein expression after treatment of leukemia cell lines with homoharringtonine. Proc AACR 49:555, 2008. e-Pub 2008.
Chen R, Chubb S, Hoch U, Hawtin RE, Fox JA, Gandhi V, Plunkett W. SNS-032, a novel inhibitor of cyclin-dependent kinases 2, 7 and 9, blocks trascription of cyclin D1 and Mcl-1 causing cell death in mantle cell lymphoma cell lines. Proc AACR 49:177, 2008. e-Pub 2008.
Micheals S, Segal D, Plunkett W, Brown D. Analysis of phosphorylated proteins after treatments of leukemia cell lines with homoharringtonine. Proc AACR 49:535, 2008. e-Pub 2008.
Sampath D, Keating M, Plunkett W, Wierda W. Cellular response to immune gene therapy using a membrane-stable, humanuzed CD154 in patients with CLL. Proc AACR 49:668, 2008. e-Pub 2008.
Liu X, Wang Y, Chubb S, Matsuda A, Plunkett W. Impact of DNA repair proteins on cell survival in response to damage induced by the DNA self-strand-breaking nucleoside analogue. Proc AACR 49:150, 2008. e-Pub 2008.
Chen R, Wierda W, Benaissa S, Hoch U, Hawtin R, Fox J, Keating M, Gandhi V, Plunkett W. Mechanism of Action of SNS-032, a Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Camparison with Flavopiridol. Blood/ASH 110(11):915A, 2007. e-Pub 2007.
Faderl S, Thomas D, Gandhi V, Borthakur G, Huang X, Plunkett W, Burger J, Cortes J, O'Brien S, Ravandi F, Bretz J, Kwari M, Kantarjian H. Phase I/II Study of Clofarabine Plus Cyclophosphamide in Adults with Relapsed and Refractory Acute Lymphoblastic Leuklemia (ALL). Blood/ASH 110(11):152B, 2007. e-Pub 2007.
Kantarjian H, Garcia-Manero G, Faderal S, Cortes J, Estrov Z, Boone P, Stuart I, Westwood R, Green S, Chiao J, Plunkett W. Phase I Study of Sapacitabine, an Oral Nucleoside Analogue, in Patients with Advanced Leukemia or Myelodysplastic Syndromes. Blood/ASH 110(11):270a, 2007. e-Pub 2007.
Faderl S, Garcia-Manero G, Gandhi V, Ravandi F, Borthakur G, Thomas D, Ferrajoli A, Estrov Z, Plunkett W, Byrd A, Kwari M, Kantarjian H. Results of an Exploratory Study of Oral (po) and Intravenous (iv) Clofarabine in Patients with Myelodysplastic Syndrome. Blood/ASH 110(11):436a, 2007. e-Pub 2007.
Lamba J, Crews K, Pounds S, Schuetz E, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R. Deoxycytidine Kinase Genotype Influences Leukemia Cell Concentration of Cytarabine 5'-Triphosphate in Pediatric AML Patients. Proc AACR 110(11):73a, 2007. e-Pub 2007.
Ewald B, Sampath D, Plunkett W. Co-localization of the Mre11-Rad50-Nbs1 complex, phosphorylated ATM, and y-H2AX may identify sites of nucleoside analogue-induced stalled replication forks. Proc AACR 48:955-956, 2007. e-Pub 2007.
Guo L, Liu X, Willmore E, Nishikawa K, Plunkett W. Induction of DNA double-strand breaks by NK314 via stabilization of topoisomerase II cleavage complexes, and inhibition of DNA-PK sensitizes cells to NK314. Proc AACR 48:954, 2007. e-Pub 2007.
Liu X, Mitsuda A, Plunkett W. ATR and DNA-PK cooperate in G2 checkpoint activation by the nucleoside analogue CNDAC. Proc AACR 48:955, 2007. e-Pub 2007.
Plunkett W, Garcia-Manero G, Faderl S, Cortes J, Boone P, Hilbe C, Green S, Chiao JH, Kantarjian H. Phase I study of sapacitabine, an oral nucleoside analogue, in patients with advanced leukemias or myelodysplastic syndromes. Proc. ASCO:108, 2007. e-Pub 2007.
Reiser H, Ray A, Shibata R, Fridland A, Plunkett W, Thamm D, Vail D, Lee W, Watkins W, Rhodes G, Desai M, Tumas D. GS-9219: A novel prodrug of 9-(2-phosphonylmethoxyethyl) guanine (PMEG) with potent activity in hematologic malignancies. Proc AACR 48:758, 2007. e-Pub 2007.
Wang Y, Liu X, Guo Y, Matsuda A, Plunkett W. Involvement of XPF/ERCC1 in the repair of 2'-cyano-2'deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC)-induced DNA strand breaks. Proc AACR 48:955, 2007. e-Pub 2007.
Chen R, C-Y T, Plunkett W. Transcription inhibition by actinomycin D as a mechanism-based approach to treatment of Bcr-Abl-positive chronic myelogenous leukemia. Proc AACR 48:764, 2007. e-Pub 2007.
Sampath D, Puduvalli V, Atadja P, Keating M, Plunkett W. Histone deacetylase inhibitors activate p73 to target chronic lymphocytic leukemia. Proc AACR 48:967, 2007. e-Pub 2007.
Tsai, C-Y, Ray A, Tumas D, Shibata R, Reiser H, Plunkett W. Intracellular metabolism of GS-9219, a membrane permeable prodrug of 9-(2-phosphonylmethoxyethyl)guanine. Proc AACR 48:757, 2007. e-Pub 2007.
J-C T, Plunkett W. Dysregulation of the S-phase checkpoint pathway potentiates myeloid leukemia cell apoptosis in response to tezacitabine. Proc AACR 47:486-487, 2006. e-Pub 2006.
Quintas-Cardama A, Kantarjian HM, Wierda W, Ferrajoli A, Chen R, Ravandi F, Plunkett W, Cortes J. A Phase II Study of Intravenous (IV) Homoharringtonine (HHT) and Imatinib (IM) in Patients (pts) with Chronic Myeloid Leukemia (CML). Blood (ASH) 108, 2006. e-Pub 2006.
A-M T, Wierda WG, O’Brien S, Plunkett W, Kipps TJ, Brown JR, Lerner S, Kantarjian H, Keating MJ. Combination of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Richter’s Syndrome and Fludarabine-Refractory Chronic Lymphocytic Leukemia. Blood (ASH) 108, 2006. e-Pub 2006.
Wang Y, Matsuda A, Plunkett W. Excision of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC) residues from DNA. Proc AACR 47:122, 2006. e-Pub 2006.
Chen R, Plunkett W. Sequential blockade of Bcr-Abl production overcomes resistance to imatinib. Proc AACR 47:709, 2006. e-Pub 2006.
Faderl S, Gandhi V, O’Brien S, Giles F, Cortes J, Plunkett W, Kantarjian HM. Clofarabine Is Active in Myelodysplastic Syndrome (MDS). Blood (ASH) 108, 2006. e-Pub 2006.
Sampath D, Du M, Keating M, Plunkett W. Fludarabine resistance in CLL is associated with non-functional p53. Proc AACR 47:884, 2006. e-Pub 2006.
Guo L, Liu X, Nishikawa K, Plunkett W. G2 arrest by NK314 and consequence of checkpoint abrogation. Proc AACR 47:490, 2006. e-Pub 2006.
Liu X, Matsuda A, Plunkett W. DNA-PK and ATR are responsible for the G2 checkpoint activation by the nucleoside analog CNDAC. Proc AACR 47:1152, 2006. e-Pub 2006.
Ewald B, Sampath D, Plunkett W. Phosphorylation of H2AX in response to a gemcitabine-induced checkpoint: increased phosphorylation subsequent to checkpoint abrogation. Proc AACR 47:491, 2006. e-Pub 2006.
Sampath D, Du M, Keating M, Plunkett W. CLL Response to DNA repair inhibition: Role for p53 and XIAP. Proc AACR 46:780, 2005. e-Pub 2005.
Liu X, Sampath D, J-C T, Batsuda A, Gesner T, Plunkett W. Abrogation of S-phase and G2 cell cycle checkpoints by small molecule inhibitors of the DNA damage kinase, Chk1. Proc AACR 46:396, 2005. e-Pub 2005.
Pan J, Plunkett W. Claspin but not Brca1 is required to mediate the gemcitabine-induced S phase checkpoint. Proc AACR 46:533, 2005. e-Pub 2005.
Guo L, Liu X, Nishikawa K, Plunkett W. Molecular basis for G2 arrest by the novel antitumor agent NK314. Proc AACR 46:396-397, 2005. e-Pub 2005.
Ewald B, Pan J, Sampath D, Plunkett W. Phosphorylation of Chk2 and H2AX during gemcitabine-induced S-phase arrest. Proc AACR 46:532, 2005. e-Pub 2005.
Moufarij M, Keating M, Plunkett W. Modulation of oxaliplatin cytotoxicity by fludarabine in chronic lymphocytic leukemia. Proc AACR 46:1181, 2005. e-Pub 2005.
Chen R, Keating M, Gandhi V, Plunkett W. Flavopiridol induces apoptosis in chronic lymphocytic leukemia (CLL) cells through the transcriptional down-regulation of anti-apoptotic proteins. Proc AACR 46:769, 2005. e-Pub 2005.
Sampath D, Rao V, Plunkett W. The role of PI3-K family members in the apoptotic response of quiescent cells to fludarabine-induced inhibition of DNA repair. Proc AACR 45:134, 2004. e-Pub 2004.
Pan J, Chen R, Plunkett W. Claspin, a Chk1 interacting protein, is involved in gemcitabine-induced S phase checkpoint activation. Proc AACR 45:538, 2004. e-Pub 2004.
Liu X, Guo Y, Li Y, Matsuda A, Huang P, Plunkett W. 7-hydroxystaurosporine (UCN-01) abrogates CNDAC-induced G2 arrest and triggers apoptosis. Proc AACR 45:538, 2004. e-Pub 2004.
Chen R, Plunkett W. A sequential blockade strategy to target the Bcr-Abl oncoprotein in chronic myelogenous leukemia by the combination of flavopiridol, homoharringtonine and STI1571. Proc AACR 45:124, 2004. e-Pub 2004.
Sampath D, Cortes J, Du M, Terry N, Shi Z, Andreeff M, Gandhi V, Plunkett W. Action of 7-hydroxystaurosporine (UCN-01) in combination with ara-C on S phase checkpoint activation and survival pathways during therapy of AML. Proc AACR 44:588, 2003. e-Pub 2003.
Chen R, Benaissa S, Plunkett W. A sequential blockade strategy to target the BCR/ABL oncoprotein in chronic myelogenous leukemia with STI1571 and the protein synthesis inhibitor homoharringtonnie. Proc AACR 44:754, 2003. e-Pub 2003.

Book Chapters

Plunkett W, Ratain M. Pharmacology. In: Cancer Medicine 8. Brian C. Decker, Inc, 587-596, 2010.
Undevia S, Ratain MJ, Plunkett W. Pharmacology. In: Cancer Medicine 7. Brian C. Decker, Inc, 617-629, 2005.
Gandhi V, Plunkett W. Clofarabine: Mechanisms of action pharmacology and clinical investigations. In: Deoxynucleoside Analogs. The Humana Press, Inc, 153-171, 2005.
Shi Z, Sampath D, Plunkett W. Dysregulating checkpoint response and survival pathway by UCN-01: Therapeutic strategies that overcoming resistance to nucleoside analogues. In: Acute Leukemias IX, Experimental Approaches and Novel Therapies. Springer-Verlag, 97-108, 2003.
Ratain MJ, Plunkett W. Pharmacology. In: Cancer Medicine 6. Brian C. Decker, Inc, 695-706, 2003.
Faderl S, Gandhi V, Kantarjian H, Plunkett W. New nucleoside analogs in clinical development. In: Cancer Chemotherapy and Biological Response Modifiers. Elsevier Science, B. V, 36-58, 2002.
Gandhi V, Plunkett W. Combination strategies for purine nucleoside analogs. In: The Chronic Lymphoid Leukemias. Marcel Dekker, Inc, 195-208, 2001.
Plunkett W, Gandhi V. Purine and pyrimidine nucleoside analogs. In: Cancer Chemotherapy and Biological Response Modifiers. Elsevier Science, B. V, 21-45, 2001.
Ratain MJ, Plunkett W. Pharmacology. In: Cancer Medicine. Williams & Wilkins, 589-601, 2000.
Plunkett W, Ruiz van Haperen VWT, Huang P, Gandhi V. Gemcitabine: A strategy for combination therapy in ovarian carcinoma. In: Ovarian Cancer 5. Isis Medical Media, Ltd, 385-394, 1998.
Koehl, Li L, Nowak B, Ruiz van Haperen V, Kornhuber B, Schwabe D, Keating M, Plunkett W, L-Y Y. Synergistic cytotoxicity using cyclophosphamide and nucleoside analogs. In: Acute Leukemias VII, Experimental Approaches and Novel Therapies. Springer-Verlag, 549-555, 1997.
Ratain MJ, Plunkett, W. Pharmacology. In: Cancer Medicine. Williams & Wilkins, 875-889, 1997.
Plunkett W, Gandhi V, Jr RC, Keating MJ. Cellular metabolism and T-cell specificity of arabinosylguanine: a review. In: Acute Leukemias VII, Experimental Approaches and Novel Therapies. Springer-Verlag, 614-620, 1997.
Gandhi V, Estey E, Seymour JF, Sampath D, Du M, Ayers M, Keating M, Plunkett W. Modulation of ara-C metabolism to improve AML response in Acute Leukemias VII. In: Experimental Approaches and Novel Therapies. Springer-Verlag, 614-620, 1997.
Plunkett W, Gandhi V. Nucleoside analogs: Cellular pharmacology, mechanisms of action and strategies for combination therapy. In: Nucleoside Analogs in Cancer Therapy. Marcel Dekker, Inc, 1-35, 1997.
Hertel LW, Kroin JS, Grossman SC, Grindey GB, Dorr AF, Storniolo AMV, Plunkett W, Gandhi V, Huang P. Synthesis and biological activity of 2',2'-difluorodeoxycytidine (Gemcitabine). In: Biomedical Frontiers of Fluorine Chemistry. American Chemical Society, 265-278, 1996.
Gandhi V, Du M, Chapman AJ, Huang P, Estey E, Keating MJ, Plunkett W. Fludarabine and ara-C combination for treatment of adult myelogenous leukemia: Pharmacokinetic and pharmacodynamic effects. In: Acute Leukemias V, Experimental Approaches and Management of Refractory Diseases. Springer-Verlag, 25-31, 1996.
Gandhi V, Estey E, Plunkett W. Modulation of arabinosylcytosine metabolism during leukemia therapy. In: Purine and Pyrimidine Metabolism in Man VIII. Plenum Press, 119-124, 1995.
Plunkett W, Saunders PP. Metabolism and action of purine nucleoside analogues. In: Anticancer Drugs: Antimetabolite Metabolism and Natural Anticancer Agents. Pergamon Press, 95-138, 1994.
Plunkett W. Preclinical characteristics of cytarabine, gemcitabine, fludarabine, and cladribine: Relevance for clinical studies. In: Innovative Antimetabolites in Solid Tumors. Springer Verlag, 11-19, 1994.
Gandhi V, Keating MJ, Estey E, Plunkett W. Modulation of ara-C metabolism by fludarabine: therapy for acute myelogenous leukemia. In: Acute Leukemias IV, Prognostic Factors. Springer-Verlag, 135-139, 1993.
Plunkett W, Gandhi V. Cellular metabolism of nucleoside analogs in CLL: Implications for drug development. In: Chronic Lymphocytic Leukemia. Marcel Dekker, 197-220, 1992.
Kemena A, Keating MJ, Plunkett W. Plasma pharmacology of fludarabine and cellular bioavailability of fludarabine triphosphate. In: Acute Leukemias: Pharmacokinetics and Management of Relapsed and Refractory Disease. Springer-Verlag, 355-358, 1992.
Kantarjian HM, Talpaz M, Wetzler M, O'Brien S, Estey E, Plunkett W, Zhang W, Keating MJ, Deisseroth A. Chronic myelogenous leukemia in blastic phase: A model of heterogeneity and resistance in acute leukemia. In: Acute Leukemias: Pharmacokinetics and Management of Relapsed and Refractory Disease. Springer-Verlag, 214-221, 1992.
Plunkett W, Gandhi V, Kantarjian H, Keating MJ. Pharmacologically guided leukemia therapy. In: Acute Leukemias: Pharmacokinetics and Management of Relapsed and Refractory Disease. Springer-Verlag, 253-257, 1992.
Heinemann V, Plunkett W. Enhanced accumulation of dFdC triphosphate in tumor cells with short retention of ara-C triphosphate. In: Acute Leukemias: Pharmacokinetics and Management of Relapsed and Refractory Disease. Springer-Verlag, 275-278, 1992.
Gandhi V, Estey E, Keating MJ, Plunkett W. Biochemical basis for combination chemotherapy. In: Acute Leukemias: Pharmacokinetics and Management of Relapsed and Refractory Disease. Springer-Verlag, 258-261, 1992.
Heinemann V, Y-Z X, Plunkett W. 2',2'-Difluorodeoxycytidine: A new antimetabolite with inhibitory activity against ribonucleotide reduction and dCMP deaminase. In: Acute Leukemias: Pharmacokinetics and Management of Relapsed and Refractory Disease. Springer-Verlag, 368-372, 1992.
Gandhi V, Huang P, Xu YZ, Heinemann V, Plunkett W. Metabolism and action of 2',2'-difluorodeoxycytidine: Self-potentiation of cytotoxicity. In: Adv Exp Med Biol. Plenum Press, 125-30, 1991.
Novotny L, Plunkett W. 9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-triphosphate. Synthesis of a triphosphate derivative from a monophosphate derivative. In: Nucleic Acid Chemistry. John Wiley & Sons, 337-340, 1990.
Plunkett W, Gandhi V, Grunewald R, Heinemann V, Estey E, Keating MJ. Pharmacologically directed design of AML therapy. In: Acute Myelogenous Leukemias: Progress and Controversies. A.R. Liss, Inc, 481-492, 1990.
Keating MJ, Kantarjian H, Estey E, Plunkett W, Trujillo J, McCredie KB. Karyotype of leukemia cells consistently predicts for response to therapy and survival following salvage therapy in acute myeloblastic leukemia. In: Hematology and Blood Transfusion, Vol 33, Acute Leukemias II. Springer-Verlag, 593-603, 1990.
Plunkett W, Gandhi V, Grunewald R, Heinemann V, Estey E, Keating MJ. Pharmacologically directed design of leukemia therapy. In: Hematology and Blood Transfusion, Vol. 33, Acute Leukemias II. Springer-Verlag, 610-613, 1990.
Novotny L, Plunkett W. 5'-Fluorosulfonylbenzoyl derivatives of therapeutic nucleoside analogs. In: Nucleic Acids Symp Ser 18. 18, 81-83, 1987.
Plunkett W, Grindey GB. Pharmacokinetics of the 5'-triphosphates of arabinosylcytosine and 2',2'-difluorodeoxycytidine in L1210 cells. In: Nucleic Acids Symp Ser 18. 18, 77-79, 1987.
Plunkett W, Keating M. Effect of m-AMSA on the cellular pharmacology of ara-CTP in human leukemic cells during therapy with high-dose ara-C. In: Adv Exp Med Biol 195, 171-5, 1986.
Plunkett W, Nowak B, Feun LG, Benjamin RS, Keating M, Freirich EJ. Modulation of arabinosyladenine metabolism by 2'-deoxycoformycin in the therapy of human acute leukemia. In: Adv Exp Med 165B, 345-50, 1984.
Plunkett W, Estey E, Keating MJ, Freireich EJ. Metabolism of ara-CTP in leukemia cells during therapy with high-dose ara-C. In: Proc. 13th International Congress of Chemotherapy. Chemother 17, 26-29, 1984.
Estey E, Plunkett W, Keating M, Anderson B, McCredie K, Freireich EJ. High-dose ara-C in refractory acute leukemia: Clinical and pharmacological correlates. In: 13th International Congress of Chemotherapy 12, 44-48, 1984.
Barlogie B, Estey E, Kantarjian J, Plunkett W, Keating M, Cabanillas F, Freireich EJ. High-dose ara-C in hematologic malignancies, the M. D. Anderson Experience. In: 13th International Congress of Chemotherapy 12, 52-56, 1984.
Plunkett W, Benjamin RS, Keating MJ, Freireich EJ. Modulation of arabinosyladenine therapy of acute myelogenous leukemia by deoxycoformycin. In: Current Chemotherapy and Immunotherapy, Volume 2, 1529-1530, 1982.
Plunkett W, Chubb S, Shewach DS, Loo TL. Comparison of the metabolism of arabinosyladenine and arabinosyl-2-fluoroadenine by human leukocytes. In: Texas J. of 30 Suppl 3, 117-128, 1978.

Books (edited and written)

Hiddemann W, Buechner T, Wormann B, Ritter J, Creutzig U, Keating MJ, Plunkett W. Acute Leukemias VII, Experimental Approaches and Novel Therapies. Springer-Verlag, 1998.
Cheson BD, Keating MJ, Plunkett W. Nucleoside Analogs in Cancer Therapy. Marcel Dekker, Inc, 1997.
Monserrat E, Plunkett W, Dighiero G, Catovsky D, Binet JL, Keating MJ. Oxford Forum: Key issues/concerns in the treatment of CLL. Leukemia & Lymphoma 22 (Suppl 2), 1996.
Peters GJ, Plunkett W. Gemcitabine Hydrochloride: Status of Preclinical Studies. Seminars in Oncology. 22 (Suppl. 11), 1995.
Plunkett W. Acute Leukemias: Pharmacokinetics and Management of Relapsed and Refractory Disease. Springer-Verlag, 1992.

Letters to the Editor

Sampath D, Plunkett W. Context-dependent actions of miR-106b in CLL. Blood 113: 6499-6500, 2009.
Damon LE, Plunkett W, Linker CA. Correspondence re: L.E. Damon, Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinosylcytosine and 1-beta-D-arabinosyluracil following repeated intravenous administration of high-dose and intermediate dose 1-beta-D-arabinofuranosylcytosine. Reply. Cancer Res 52: 3818-3820, 1992.

Less

Selected Presentations & Talks

Local Presentations

2016. Moon Shots Program Leaders Share the Good News: Leukemia-CLL. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Deletion 11q22-23: the Achilles heal of CLL A mechanism-based strategy to target a genetic lesion. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2012. Targeting Homologous Recombination Deficiency to Achieve Therapeutic Specificity. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2010. Targeting Homologous Recombination to Achieve Therapeutic Specificty. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2010. Drug Induced Synthetic Lethality. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2009. Lowering the therapeutic threshold to apoptosis. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2007. Rational drug development: New combination and new agents. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2006. Sapacitabine: A stealth nucleoside analogue. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2005. Pharmacologic Rationales for the Design of Leukemia Therapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2005. Purine Nucleoside Analogs. Conference. Texas Children's Hospital, The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2004. A novel trigger for the G2 checkpoint. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2002. Cell Cycle Checkpoints as Therapeutic Targets: The Case for UCN-01. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2002. Mechanism-Based Rationales for Combination Therapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2002. Cell Cycle Checkpoints as Therapeutic Targets. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2001. Cell cycle checkpoint pathways as therapeutic targets. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2000. Therapeutic strategies that dysregulate cell cycle control. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
1997. Mechanism-Based Rationale for Combination Chemotherapy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
1997. Developmental Pharmacology. Conference. Prospective for the 21st century. Houston, TX, US.

National Presentations

2013. Discussant: Actions of New Nucleosides. Invited. Gordon Research Conference on Nucleosides, Nucleotides and Oligonucleotides. Newport, RI, US.
2013. Targets of CLL Therapy. Invited. CLL Global Research Foundation. Houston, TX, US.
2012. Targeted Chemotherapy. Invited. US-European Alliance for CLL Therapy. Amsterdam, Netherlands, US.
2012. Nucleoside Transporters - Relevance to Cancer Therapeutics. Invited. Clovis Pharmaceuticals. Chicago, IL, US.
2012. Rationale for omacetaxine in hematological malignancies. Invited. Teva Pharmaceuticals. Houston, TX, US.
2011. Emerging New Targets for CLL. Conference. CLL Global Reseach Foundation Symposium. San Diego, CA, US.
2011. Sapacitabine: mechanism of action and rationales for future applications. Invited. Cyclacel Pharmaceuticals, Inc. New York City, NY, US.
2010. Targeting homologous recombination deficiency with drug action. Invited. Sanford Burnham Research Institute. La Jolla, CA, US.
2009. Gordon Research Conference on Nucleosides, Nucleotides, and Oligonucleotides. Invited. Gordon Research Conference. Newport, RI, US.
2008. Targeting Anti-apoptotic Proteins in CLL. Invited. Leukemia 2008. Houston, TX, US.
2008. New Approaches to Leukemia Therapy. Invited. Medical University of South Carolina, Hollings Cancer Center. Charleston, SC, US.
2006. Rationale for new Treatment Strategies in CLL. Invited. Satellite Symposium to American Society of Hematology. Orlando, FL, US.
2005. Development of Therapeutic Nucleosides in Cancer. Invited. Gilead Sciences. Foster City, CA, US.
2005. DNA strand breaking mechanism. Invited. Gordon Research Conference on Nucleosides, Nucleotides, and Oligonucleotides Acids. Newport, RI, US.
2005. Sequential Blockade of Oncogenic Kinases. Invited. American Association for Cancer Research, Educational Session, Transcription as a Target for Cancer Therapeutics. Anaheim, CA, US.
2003. Novel Pharmacologic Approaches. Invited. American Association for Cancer Research, Symposium on New Directions in Cancer, Organ Site Research from the Laboratory to the Clinic-Chronic Lymphocytic Leukemia. Washington, US.
2003. Enzyme-Focused Strategies. Invited. Gordon Research Conference on Purines, Pyrimidines and Related Substances. Newport, RI, US.
2003. Use of Fludarabine in Cancer Therapy. Invited. Tandem Bone Marrow Transplantation Meetings. Keystone, CO, US.
2002. Cell cycle active agents. Invited. Leukemia 2002-Toward the Cure. Miami, FL, US.
2002. New Purine Nucleoside Analogs-Rationale of Combinations. Invited. New Directions in Acute Leukemia. Miami, FL, US.
2002. Rationale for Development of Tezacitabine. Invited. Chiron Corporation. Emeryville, CA, US.
2002. Checkpoint Responses in Therapeutic Intervention. Invited. AACR Education Symposium. San Francisco, CA, US.
2002. Mechanism-Based Design of Combination Therapies. Invited. Community Cancer Care, Inc., The Science of Oncology Care. Dallas, TX, US.
2001. Nucleoside Analogs: Novel cell cycle dependent mechanisms. Invited. Gordon Research Conference on Purines and Pyrimidines. Newport, RI, US.
2001. Pharmacologic Issues in New Drug Development. Invited. Chronic Lymphocytic Leukemia State of the Science Workshop-NCI. Bethesda, MD, US.
2001. North Central Cancer Treatment Group, Novel Therapeutics Committee. Invited. Studies with UCN-01. Rochester, MN, US.
1999. DNA repair: extending the range of cycle-specific drugs in indolent diseases. Invited. American Society of Hematology Education Program on Molecular Pharmacology of Novel Anti-Cancer Drugs. New Orleans, LA, US.
1999. Biochemical Predictors of Response to Gemcitabine. Invited. Bladder Cancer Consultants Meeting. Gleneagles.
1999. DNA repair; extending the range of cell cycle specific agents. Invited. Meet the Expert-Sunrise Session, American Association for Cancer Research. Philadelphia, PA, US.
1998. Phase I study of GW506U78, Day 1, 3, & 5 Schedule; and Phase I Study of GW506U78 Plus Fludarabine. Invited. National Cancer Institute, NIH. Bethesda, MD, US.
1997. Mechanisms of Therapeutic Nucleosides: Gemcitabine. Invited. Gordon Research Conference on Purines, Pyrimidines, and Related Substances. Newport, RI, US.
1997. Gemcitabine: Mechanism-based strategies combinations for ovarian cancer. Invited. 6th Forum on Ovarian Cancer, Helene Harris Memorial Trust. Los Angeles, CA, US.
1996. Antimetabolites: Renewed Interest. Invited. Leukemia...The Next Questions. New Orleans, LA, US.
1995. Pharmacologic Basis for Protocol Design. Invited. Children's Cancer Group Meeting. Houston, TX, US.

International Presentations

2013. Fludarabine: From Bench to Bedside. Invited. Studio E.R. Congressi. Bologna, IT.
2012. Pathophysiology of CLL. Invited. Ospedale San Raffaele. Milan, IT.
2011. Optimizing Trial Design in CLL Mechanism based strategies to target a genetic lesion. Invited. International Workshop for CLL. Houston, US.
2009. DNA strand breaking nucleoside. Invited. 13th International Symposium on Purine & Pyrimidine Metabolism in Man. Stockholm, SE.
2008. Yin and Yang of CLL Therapy. Invited. Hematology Association of Australia and New Zealand. Perth, AU.
2008. Development of CLL Therapeutics. Invited. U.S/European Alliance for CLL. Lake Orta, IT.
2007. Nucleoside Analogues: Not Dead Yet. Invited. International Workshop of Chronic Lymphocyctic Leukemia. London, GB.
2007. Gemcitabine: tracking its activation. Invited. 13th International Charles Heidelberger Symposium on Cancer Research. New York City, US.
2005. Inhibition of DNA Repair as a Therapeutic Strategy. Invited. International Working Group on Chronic Lymphocytic Leukemia. New York, US.
2005. Using Cellular Pharmacology in the Evaluation of New Agents. Invited. Satellite Symposium to European Hematology Association. Stockholm, SE.
2004. Synergistic Cytotoxicity with Combinations: Incorporating Nucleoside Analogs. Invited. Third Annual Future of Breast Cancer: International Congress. Southampton, BM.
2004. Targeting DNA repair in leukemia therapy. Invited. 9th Congress of the European Hematology Association, Satellite Symposium. Geneva, CH.
2003. Rational development of new drug combinations in hematologic malignancies. Invited. Focus on Lymphoproliferative and Myeloproliferative Disorders. Salerno, IT.
2003. Evaluating Emerging New Drugs in the Management of Lymphoid Malignancies. Invited. 8th Congress of the European Hematology Association. Lyon, FR.
2002. Strategies that Target Cell Cycle Regulation. Invited. Satellite Symposium, European Hematology Association. Florence, IT.
2002. A rational approach to combination therapy with gemcitabine. Invited. ASCO Integrated Education Session. Orlando, US.
2002. Insights into mechanisms of drug activity and drug interactions. Invited. IX International Workshop on CLL. San Diego, US.
2001. The next new drug....Preclinical data. Invited. New Drugs in Hematologic Malignancies. Bologna, IT.
2001. New Agents in Malignant Hematology and Drug scheduling--does it really matter?. Invited. Hematology Society of Australia and New Zealand Symposium. Brisbane, AU.
2001. Therapeutic strategies that dysregulate cell cycle control. Invited. 4th International Symposium on Leukemia and Lymphoma-Molecular Pharmacology and New Treatment Modalities. Amsterdam, NL.
2001. Therapeutic strategies that dysregulate cell cycle control. Invited. 4th International Symposium on Acute Leukemias IX Basic Research, Experimental Approaches and Novel Therapies. Munich, DE.
2000. New drugs active in hematologic malignancies. Invited. Second International Meeting on Recent Advances in Hematology. San Giovanni Rotondo, IT.
2000. Gemcitabine: Mechanism of action and pharmacology. Invited. 10th International Congress on Anti-Cancer Treatment, New Drugs and GI Malignancies. Paris, FR.
2000. Focusing on pre-transplant Immunosuppression: Fludarabine/purine analogues-mechanism of action and immunosuppressive properties. Invited. First International Workshop on Non-Myeloablative Stem Cell Transplantation. Dennery, LC.
1999. Pharmacodynamics of Nucleoside Analogs. Invited. International Workshop on Chronic Lymphocytic Leukemia. Paris, FR.
1999. Rational Design of New Drug Combinations. Invited. International Workshop on Indolent Lymphoma. Bologna, IT.
1999. Exploitable Mechanisms in Leukemia. Invited. Second International Acute Leukemia Forum. Toronto, CA.
1999. Rationales for Combination Therapies. Invited. Symposium on New and Emerging Treatment Strategies in Hematological Malignancies, European Association for Hematology. Barcelona, ES.
1999. Poster Discussion: Phase I Studies of Antimetabolites. Invited. American Society of Clinical Oncology. Atlanta, US.
1998. Mechanistic rationales for combination therapy. Invited. 7th National Conference in Nasopharngeal Cancer. Guangzhou, CN.
1998. Rationales of Combination Therapies. Invited. 1st International Forum on AML. Siguenza, ES.
1997. Rationales for Combination Therapies. Invited. International Society of Hematology, Symposium on Innovative Strategies in Hematologic Malignancies. Stockholm, SE.
1997. Therapeutic deoxynucleoside analogs: mechanism of cytotoxicity. Invited. 9th International Symposium on Purine and Pyrimidine Metabolism in Man. Gmunden, AT.
1997. Therapeutic Resistance. Invited. VIIth International Workshop on Chronic Lymphocytic Leukemia. Crete, GR.
1997. Ara-G: cellular metabolism and T-ALL specificity. Invited. Acute Leukemias VII, Experimental Approaches and Novel Therapies. Muenster, DE.
1997. Characteristics and mechanisms of action of purine analogs, and rationales for combination therapy. Invited. German Chronic Leukemia Group Workshop. Muenster, DE.
1996. Current Status of Anticancer Antimetabolites. Invited. International Congress of Surgeons 30th Biennial Congress. Kyoto, JP.
1996. Gemcitabine: Actions and Interactions. Invited. XII International Roundtable on Nucleosides and Nucleotides and Their Biological Applications. La Jolla, US.
1996. Gemcitabine: Metabolism and Mechanisms of Action. Invited. Symposium on Gemcitabine: Rationales for Clinical Trial Design and Evaluation. Amsterdam, NL.
1996. New Developments in Lymphoproliferative Diseases, Pharmacology of Fludarabine and other Nucleoside Analogues. Invited. II National in Oncology. Madrid, ES.
1995. Intracellular Pharmacodynamics in Leukemia Therapy. Invited. Kyowa Hakko Kyogo, Ltd., Research Division. Misima, JP.
1995. Intracellular Pharmacodynamics in Leukemia Therapy. Invited. 37th Annual meeting of Japanese Society of Clinical Hematology. Kyoto, JP.
1995. Actions and Clinical Applications of New Purine Nucleoside Analogues in Lymphoid Malignancies. Invited. Symposium on Chronic Lymphoid Neoplasias, International Society of Hematology. Istanbul, TR.
1995. Why Drugs Work in CLL, and Apoptosis in B Cell CLL. Invited. The Oxford Forum. Key Issues/Concerns in the Treatment of CLL. Oxford, GB.
1995. DNA repair: a target for novel nucleosides. Invited. American Association for Cancer Research Symposium, New Strategies and Targets for Therapy of Cancer. Toronto, CA.
1995. Fludarabine: Mechanisms of Action. Invited. Second International Symposium on Drug Resistance in Leukemia and Lymphoma. Amsterdam, NL.

Formal Peers

2012. Targeting the Pathophysiology of CLL. Invited. Feinstein Institute for Medical Research. Great Neck, NY, US.
2010. Drug Induced Synthetic Lethality. Invited. Methodist Hospital Research Institute. Houston, TX, US.
2008. New Approaches to Leukemia Therapy. Invited. Medical University of South Carolina hollings Cancer Center. Charleston, SC, US.
2005. Cell Cycle Checkpoints as Targets in Cancer Therapeutics. Invited. The University of St. Thomas. St. Paul, MN, US.
2004. New Strategies and Targets in Chemotherapy of Leukemia. Invited. Universita Via-Salute San Raffaele. Milan, IT.
2004. A Novel Trigger for the G2 Checkpoint Pathway. Invited. The University of Illinois - Chicago. Chicago, IL, US.
2002. Cell cycle Checkpoint Pathways as Therapeutic Targets. Invited. The University of Manitoba. Winnipeg, CA.
2002. Cell Cycle Checkpoint Pathways as Therapeutic Targets. Invited. The University of Texas Health Science Center. Houston, TX, US.
2001. New drug development in leukemia and lymphoma. Invited. Peter MacCallum Cancer Institute. Melbourne, AU.
2001. Gemcitabine mechanism of action and synergism with platinum compounds. Invited. Eli Lilly and Company. Indianapolis, IN, US.
2001. Pharmacologic approaches to the design of combination therapies. Invited. University of Vermont. Burlington, VT, US.
2001. Cancer Therapeutics: Cell biology and mechanism of activity. Invited. University of Massachusetts. Worcester, MA, US.
2001. Cell cycle controls as therapeutic targets. Invited. Dartmouth Hitchcock Medical Center. Lebanon, NH, US.
2001. Metabolism and actions of ethynylcytidine. Invited. Glaxo Smith Kline. King of Prussia, PA, US.
2001. Cell cycle checkpoints as therapeutic targets. Invited. Icos Corporation. Bothell, WA, US.
2001. Dysregulation of cell cycle control. Invited. Mayo Clinic Cancer Center. Rochester, MN, US.
2001. Therapeutic strategies that dysregulate cell cycle control mechanisms. Invited. University of Miami. Miami, FL, US.
2000. Therapeutic strategies that dysregulate cell cycle control. Invited. The New York Presbyterian Cornell Medical School. New York, NY, US.
2000. Therapeutic strategies that dysregulate cell cycle control. Invited. The Ruttenberg Cancer Center. New York, NY, US.
2000. Sant' Anna, Therapeutic strategies that dysregulate cell cycle control. Invited. Universita degli Studi di Pisa. Pisa, IT.
1999. DNA Repair: Extending the range of cycle-specific drugs in indolent diseases. Invited. American Society of Hematology. New Orleans, LA, US.
1998. Rationales for the design of combination therapies. Invited. Chinese University of Hong Kong, Department of Med. Shatin, HK.
1998. Gemcitabine: Action Mechanisms and Strategies for Clinical Evaluation. Invited. Fukui Medical University. Fukui, JP.
1998. Mechanistic Rationales for Combination Therapy. Invited. Kanazawa University. Kanazawa, JP.
1998. DNA Repair: Extending the Range of Nucleoside Analogs. Invited. University of Hokkaido. Sapporo, JP.
1998. Mechanistic Basis for Clinical Trial Design. Invited. W. W. Cross Cancer Center, University of Alberta. Edmonton, Alberta, CA.
1998. Rationales for Combination Therapy. Invited. Universita degli Studi di Firenze. Florence, IT.
1998. DNA Repair: Extending the Range of Nucleoside Analogs. Invited. Case Western Reserve University. Cleveland, OH, US.
1997. Mechanistic Basis for Synergistic Activity. Invited. National Cancer Institute. Rockville, MD, US.
1997. Gemcitabine: Mechanism-based Combinations for Non-cell Cycle Specific Activity. Invited. University of Arkansas. Fayetteville, AR, US.
1997. Pharmacokinetics and clinical application of purine analogues in leukemia and lymphoma. Invited. University of Athens. Athens, GR.
1996. How to make CLL therapy work better. Invited. National Cancer Institute--. Bethesda, MD, US.
1996. Studies on ara-C/cladribine: Implications for the Treatment of AML. Invited. St. Jude Children's Research Hospital. Memphis, TN, US.
1996. Gemcitabine: Mechanisms of Action and Therapeutic Strategies. Invited. Emory University. Atlanta, GA, US.
1996. Pharmacologic Basis for Therapeutic Design. Invited. Ohio State University. Columbus, OH, US.
1995. Molecular Pharmacology in the Design of Anticancer Therapies. Invited. University of North Texas. Denton, TX, US.
1995. Pharmacologic Strategy for Leukemia Protocol Design. Invited. Free University of Amsterdam. Amsterdam, NL.

Less

Grant & Contract Support

Date:	2022 - 2023
Title:	Project 2: Curative Targeted Therapy of CLL
Funding Source:	The University of Texas MD Anderson Cancer Center, Moon Shots Program
Role:	Principal Investigator-MDACC

Date:	2022 - 2024
Title:	PHARMACOLOGICAL INHIBITION OF GAB1 IN CHRONIC LYMPHOCYTIC LEUKEMIA
Funding Source:	NIH/NCI
Role:	Co-I
ID:	GRANT13485736

Date:	2022 - 2024
Title:	Apoptotic Correlative Analysis of Fadraciclib (MD Anderson CLL Subjects only) in a Phase ½ Trial
Funding Source:	Cyclacel Pharmaceuticals
Role:	PI

Date:	2021 - 2022
Title:	Project 3: Targeting CLL Pathophysiology
Funding Source:	The University of Texas MD Anderson Cancer Center, Moon Shots Program
Role:	Principal Investigator-MDACC

Date:	2019 - 2022
Title:	Evaluation of Biomarkers of CYC065 pharmacodynamics in the Phase 1 trial
Funding Source:	Cyclacel Pharmaceuticals
Role:	PI

Date:	2019 - 2023
Title:	Strategies to understand and target Bcl-2 Family Proteins in CLL
Funding Source:	CLL Global Research Foundation
Role:	PI

Date:	2017 - 2020
Title:	Single agent and mechanism-based combinations of CYC065 in chronic lymphocytic leukemia
Funding Source:	Cyclacel
Role:	PI

Date:	2014 - 2015
Title:	Creating Novel Translation Inhibitors to Target Pro-Survival Oncoproteins
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI
ID:	RP130660

Date:	2013 - 2018
Title:	Strategies to target the pathophysiology of CLL
Funding Source:	CLL Global Research Foundation
Role:	PI

Date:	2013 - 2020
Title:	SPORE - University of Texas MD Anderson Cancer Center - Development Research Program (DRP)
Funding Source:	NIH/NCI
Role:	Co-Leader, Development Research Program
ID:	P50 CA100632-12

Date:	2013 - 2020
Title:	CLL moon shot - ibrutinib
Funding Source:	MDACC Moon Shot Program
Role:	PI

Date:	2013 - 2020
Title:	SPORE University of Texas MD Anderson Cancer Center - Career Development Program (CDP)
Funding Source:	NIH/NCI
Role:	Co-Leader, Career Development Program
ID:	P50 CA100632

Date:	2013 - 2022
Title:	Cancer Center Support (Core) Grant
Funding Source:	NIH/NCI
Role:	Program Leader
ID:	P30 CA16672

Date:	2012 - 2014
Title:	Delivery System for Nucleoside Monophosphates
Funding Source:	Center for Targeted Therapy-TI-3D
Role:	Co-PI

Date:	2012 - 2017
Title:	Chronic Lymphocytic Leukemia Research Consortium
Funding Source:	NIH
Role:	Project Leader
ID:	P01 CA81534

Date:	2012 - 2016
Title:	Sapacitabine therapy to create synthetic lethality in DNA repair-deficient CLL
Funding Source:	NIH
Role:	Co-PI
ID:	1R01 CA163802

Date:	2011 - 2013
Title:	Investigations of the multi-kinase inhibitor TG02 in CLL
Funding Source:	Tragara Pharmaceuticals
Role:	PI

Date:	2011 - 2015
Title:	A Novel Preoperative Platform in Pancreatic Cancer for Mechanistic Studies
Funding Source:	Lustgarten Foundation for Pancreatic Cancer Research
Role:	Co-I

Date:	2011 - 2018
Title:	Biochemical Basis for Therapeutic Activity
Funding Source:	NIH
Role:	PI
ID:	5R01 CA28596

Date:	2008 - 2013
Title:	SPORE Grant in Leukemia
Funding Source:	NIH
Role:	Project Leader
ID:	5 P50 CA100632

Date:	2008 - 2014
Title:	A phase I-II study of oxaliplatin, fludarabine, cytarabine, and retuximab in patients with Richter's transformation, prolymphocytic leukemia, relapsed or refractory chronic lymphocytic leukemia
Funding Source:	UCSD Sub-contractor
Role:	PI

Title:	Targeting the Bcl-2 Family Proteins in CLL
Funding Source:	CLL Global Research Foundation
Role:	PI

CV information above last modified March 27, 2025

William Plunkett, Ph.D.

About Dr. Plunkett

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

William Plunkett, Ph.D.

About Dr. Plunkett

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Editorials

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer